<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Extended‐field radiotherapy for locally advanced cervical cancer - Thamronganantasakul, K - 2018 | Cochrane Library</title> <meta content="Extended‐field radiotherapy for locally advanced cervical cancer - Thamronganantasakul, K - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012301.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Extended‐field radiotherapy for locally advanced cervical cancer - Thamronganantasakul, K - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012301.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012301.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Extended‐field radiotherapy for locally advanced cervical cancer" name="citation_title"/> <meta content="Komsan Thamronganantasakul" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Narudom Supakalin" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Chumnan Kietpeerakool" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="kiet_ji@hotmail.com" name="citation_author_email"/> <meta content="Porjai Pattanittum" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Pisake Lumbiganon" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD012301.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012301.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012301.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012301.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Chemoradiotherapy; Disease Progression; Lymph Nodes [pathology]; Lymphatic Irradiation [adverse effects, *methods]; Lymphatic Metastasis [pathology, *radiotherapy]; Neoplasm Recurrence, Local [pathology, radiotherapy]; Pelvis; Progression‐Free Survival; Randomized Controlled Trials as Topic; Uterine Cervical Neoplasms [drug therapy, mortality, pathology, *radiotherapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012301.pub2&amp;doi=10.1002/14651858.CD012301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012301\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012301\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ja","pl","fr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012301.pub2",title:"Extended\\u2010field radiotherapy for locally advanced cervical cancer",firstPublishedDate:"Oct 26, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012301.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012301.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012301.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012301.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012301.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012301.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012301.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012301.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012301.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012301.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4132 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012301.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-sec-0069"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-sec-0124"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/appendices#CD012301-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/table_n/CD012301StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/table_n/CD012301StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Extended‐field radiotherapy for locally advanced cervical cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information#CD012301-cr-0002">Komsan Thamronganantasakul</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information#CD012301-cr-0003">Narudom Supakalin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information#CD012301-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Chumnan Kietpeerakool</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information#CD012301-cr-0005">Porjai Pattanittum</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information#CD012301-cr-0006">Pisake Lumbiganon</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information/en#CD012301-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012301.pub2">https://doi.org/10.1002/14651858.CD012301.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012301-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012301-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012301-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012301-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012301-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012301-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012301-abs-0001" lang="en"> <section id="CD012301-sec-0001"> <h3 class="title" id="CD012301-sec-0001">Background</h3> <p>The para‐aortic lymph nodes (located along the major vessels in the mid and upper abdomen) are a common place for disease recurrence after treatment for locally advanced cervical cancer. The para‐aortic area is not covered by standard pelvic radiotherapy fields and so treatment to the pelvis alone is inadequate for women at a high risk of occult cancer within para‐aortic lymph nodes. Extended‐field radiotherapy (RT) widens the pelvic RT field to include the para‐aortic lymph node area. Extended‐field RT may improve outcomes in women with locally advanced cervical cancer by treating occult disease in para‐aortic nodes not identified at pretreatment imaging. However, RT treatment of the para‐aortic area can cause severe adverse effects, so may increase harms. </p> <p>Studies of pelvic chemoradiotherapy (CRT) demonstrated improved survival rates compared to pelvic RT alone. CRT is now the standard of care in the treatment of locally advanced cervical cancer. Studies comparing pelvic RT alone (without concurrent chemotherapy) with extended‐field RT should therefore be viewed with caution, since they compare treatments against what is now substandard treatment (pelvic RT alone). This review should therefore be read with this in mind and comparisons with pelvic RT cannot be extrapolated to pelvic CRT. </p> </section> <section id="CD012301-sec-0002"> <h3 class="title" id="CD012301-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and toxicity of extended‐field radiotherapy in women undergoing first‐line treatment for locally advanced cervical cancer. </p> </section> <section id="CD012301-sec-0003"> <h3 class="title" id="CD012301-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 7), MEDLINE via Ovid (1946 to August week 4, 2018), and Embase via Ovid (1980 to 2018, week 35). We checked registers of clinical trials, grey literature, conference reports, and citation lists of included studies to August 2018. </p> </section> <section id="CD012301-sec-0004"> <h3 class="title" id="CD012301-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) evaluating the effectiveness and toxicity of extended‐field RT for locally advanced cervical cancer. </p> </section> <section id="CD012301-sec-0005"> <h3 class="title" id="CD012301-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected potentially relevant RCTs, extracted data, assessed risk of bias, compared results, and made judgements on the quality and certainty of the evidence for each outcome. Any disagreements were resolved by discussion or consultation with a third review author. </p> </section> <section id="CD012301-sec-0006"> <h3 class="title" id="CD012301-sec-0006">Main results</h3> <p>Five studies met the inclusion criteria. Three included studies compared extended‐field RT versus pelvic RT, one included study compared extended‐field RT with pelvic CRT, and one study compared extended‐field CRT versus pelvic CRT. </p> <p><b>Extended‐field radiotherapy versus pelvic radiotherapy alone</b><br/> Compared to pelvic RT, extended‐field RT probably reduces the risk of death (hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.48 to 0.94; 1 study; 337 participants; moderate‐certainty evidence) and para‐aortic lymph node recurrence (risk ratio (RR) 0.36, 95% CI 0.18 to 0.70; 2 studies; 477 participants; moderate‐certainty evidence), although there may or may not have been improvement in the risk of disease progression (HR 0.92, 95% CI 0.69 to 1.22; 1 study; 337 participants; moderate‐certainty evidence) and severe adverse events (RR 1.05, 95% CI 0.79 to 1.41; 2 studies; 776 participants; moderate‐certainty evidence). </p> <p><b>Extended‐field radiotherapy versus pelvic chemoradiotherapy</b><br/> In a comparison of extended‐field RT versus pelvic CRT, women given pelvic CRT probably had a lower risk of death (HR 0.50, 95% CI 0.39 to 0.64; 1 study; 389 participants; moderate‐certainty evidence) and disease progression (HR 0.52, 95% CI 0.37 to 0.72; 1 study; 389 participants; moderate‐certainty evidence). Participants given extended‐field RT may or may not have had a lower risk of para‐aortic lymph node recurrence (HR 0.44, 95% CI 0.20 to 0.99; 1 study; 389 participants; low‐certainty evidence) and acute severe adverse events (RR 0.05, 95% CI 0.02 to 0.11; 1 study; 388 participants; moderate‐certainty evidence). There were no clear differences in terms of late severe adverse events among the comparison groups (RR 1.06, 95% CI 0.69 to 1.62; 1 study; 386 participants; moderate‐certainty evidence). </p> <p><b>Extended‐field chemoradiotherapy versus pelvic chemoradiotherapy</b><br/> Very low‐certainty evidence obtained from one small study (74 participants) showed that, compared to pelvic CRT, extended‐field CRT may or may not have reduced risk of death (HR 0.37, 95% CI 0.14 to 0.96) and disease progression (HR 0.25, 95% CI 0.07 to 0.87). There were no clear differences between the groups in the risks of para‐aortic lymph node recurrence (RR 0.19, 95% CI 0.02 to 1.54; very low‐certainty evidence) and severe adverse events (acute: RR 0.95, 95% CI 0.20 to 4.39; late: RR 0.95, 95% CI 0.06 to 14.59; very low‐certainty evidence). </p> </section> <section id="CD012301-sec-0007"> <h3 class="title" id="CD012301-sec-0007">Authors' conclusions</h3> <p>Moderate‐certainty evidence shows that, compared with pelvic RT alone, extended‐field RT probably improves overall survival and reduces risk of para‐aortic lymph node recurrence. However, pelvic RT alone would now be considered substandard treatment, so this result cannot be extrapolated to modern standards of care. Low‐ to moderate‐certainty evidence suggests that pelvic CRT may increase overall and progression‐free survival compared to extended‐field RT, although there may or may not be a higher rate of para‐aortic recurrence and acute adverse events. Extended‐field CRT versus pelvic CRT may improve overall or progression‐free survival, but these findings should be interpreted with caution due to very low‐certainty evidence. </p> <p>High‐quality RCTs, comparing modern treatment techniques in CRT, are needed to more fully inform treatment for locally advanced cervical cancer without obvious para‐aortic node involvement. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012301-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012301-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012301-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012301-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012301-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012301-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012301-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012301-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012301-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012301-abs-0005" lang="en"> <h3>Does extended‐field radiotherapy reduce death from locally advanced cervical cancer and what are the side effects? </h3> <p><b>The issue</b><br/> Radiotherapy (RT) to the pelvis is used to treat cervical cancer. However, pelvic RT will not treat cancer that has spread to para‐aortic lymph nodes (lymph nodes lying along main blood vessels in the mid and upper stomach), since these are outside the target area (field) of RT. Extended‐field RT targets areas containing both pelvic and para‐aortic lymph nodes. Widening the RT field to include the para‐aortic area may reduce the risk of cancer returning. </p> <p>Chemotherapy is now normally given at the same time as RT for the treatment of cervical cancer (concurrent chemotherapy) and the combine treatment is called chemoradiotherapy (CRT). This is now standard treatment because studies have shown that addition of chemotherapy during RT improved survival for women with cervical cancer thought to be confined to the pelvis. Older studies, which compared treatments with pelvic RT alone, would not now be considered the standard of care for women well enough to have CRT. We cannot assume that results from studies which compared extended‐field RT with pelvic RT apply to modern CRT treatments. </p> <p><b>The aim of this review</b><br/> In women with locally advanced cervical cancer, does extending the RT field to cover the para‐aortic area reduce the risk of death from cervical cancer and what are the harms? </p> <p><b>Study characteristics</b><br/> We searched databases from their inception to August 2018 and found five studies that met the inclusion criteria. Three studies compared extended‐field RT versus pelvic RT. None of these three studies compared against the current gold‐standard of pelvic CRT. One study compared extended‐field RT versus pelvic CRT and one study compared extended‐field CRT versus pelvic CRT. </p> <p><b>What were the main findings?</b><br/> Compared with pelvic RT alone, women given extended‐field RT may have been less likely to die and probably were less likely to have a cervical cancer come back (recurrence) in the para‐aortic lymph nodes. However, extended‐field RT may have made little or no difference to how often their cancer recurred elsewhere and how often they experience severe side effects. </p> <p>Pelvic CRT is the modern standard of treatment for locally advanced cervical cancer. In a comparison of extended‐field RT alone versus pelvic CRT, women given pelvic CRT were probably less likely to die or have recurrence of their cancer. Women given extended‐field RT alone may have been less likely to experience a recurrence within the para‐aortic lymph nodes and have had adverse events during or shortly after treatment. There were no clear differences regarding the late adverse events between the two groups. </p> <p>Women given extended‐field CRT may or may not have been less likely to die or have cancer progression than those women pelvic CRT. There were no clear differences in the chances of experiencing a cancer recurrence in the para‐aortic lymph nodes and severe side effects between the groups. </p> <p><b>Certainty of the evidence</b><br/> The evidence for outcomes in the comparison of extended‐field RT alone versus pelvic RT alone were of moderate certainty. In the comparison of extended‐field RT versus pelvic CRT, the evidence regarding the survival and side effects were of moderate certainty. The evidence for para‐aortic recurrence was of low certainty. The evidence for all outcomes in a comparison of extended‐field CRT versus pelvic CRT were of very‐low certainty because of concerns regarding the high risk of bias and results coming from a single trial of very few women. </p> <p><b>What were the conclusions?</b><br/> We are moderately certain that, compared with pelvic RT alone, extended‐field RT probably improves overall survival and reduces risk of para‐aortic lymph node recurrence. However, pelvic RT alone would now not be considered the standard of care in women well enough to receive CRT, so these results should be reviewed with caution and cannot be extrapolated to modern treatment techniques. </p> <p>Low‐ to moderate‐certainty evidence supports the use of pelvic CRT rather than extended‐field RT alone, as it appears to reduce the risk of death and cancer progression. The likelihood of experiencing unwanted side effects during treatment was higher among women receiving pelvic CRT than extended‐field RT. Evidence comparing extended‐field CRT to pelvic CRT was very low certainty regarding outcomes and it may or may not improve survival. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012301-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012301-sec-0130">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012301-sec-0191">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012301-sec-0130"></div> <h3 class="title" id="CD012301-sec-0131">Implications for practice</h3> <section id="CD012301-sec-0131"> <p>The studies in this review largely used now non‐standard radiotherapy (RT) and chemotherapy regimens. Therefore, it is difficult to draw any firm conclusions. However, based on existing evidence presented in this review: </p> <p> <ul id="CD012301-list-0031"> <li> <p>pelvic chemoradiotherapy (CRT) probably has a lower risk of death and disease progression than extended‐field RT in treatment of women with locally advanced cervical cancer, despite a probable increase in acute severe adverse events; </p> </li> </ul> <ul id="CD012301-list-0032"> <li> <p>extended‐field RT may improve survival in women who are unable to have concurrent chemotherapy. This is likely due to better control of the para‐aortic area when compared to pelvic RT alone. However, this finding should be interpreted with caution as it was obtained from one study in which approximately one‐third of women did not undergo any para‐aortic lymph node evaluation; </p> </li> </ul> <ul id="CD012301-list-0033"> <li> <p>although extended‐field CRT may improve overall and progression‐free survival when compared to pelvic CRT, the benefits and harm of extended‐field CRT should be regarded with caution due to a small number of reported adverse events and serious imprecision of data noted in one small included study. Further research is highly likely to have an important impact on the estimates of treatment effects and may alter existing estimates in this comparison. </p> </li> </ul> </p> </section> <h3 class="title" id="CD012301-sec-0132">Implications for research</h3> <section id="CD012301-sec-0132"> <p>High‐quality randomised controlled trials (RCTs) are needed to inform treatment of locally advanced cervical cancer in the era of modern RT techniques. Although CRT could improve survival, some women may not be able to tolerate this treatment combination. There is a need for an adequately sized RCT for evaluating the effectiveness and safety of an extended‐field RT given in a selected group of women suitable for RT treatment alone who have undergone adequate assessment of para‐aortic lymph nodes. </p> <p>Due to the lack of sufficient data, further high‐quality RCTs are required to confirm the effectiveness and safety of an extended‐field CRT compared to standard pelvic CRT before it can be considered for use outside of clinical trials. </p> <p>In addition, the benefits and harms of extended‐field RT need to be reassessed in further randomised studies using modern chemotherapy regimens and modern RT techniques (e.g. volumetric‐modulated arc therapy (VMAT) and tomotherapy which are likely to allow extended‐field RT to be better tolerated). Importantly, any further studies should include a mandatory assessment on the impact on quality of life and cost‐effectiveness. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012301-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012301-sec-0036"></div> <div class="table" id="CD012301-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Extended‐field radiotherapy compared to pelvic radiotherapy for locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Extended‐field radiotherapy versus pelvic radiotherapy for locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant:</b> women with locally advanced cervical cancer undergoing radiotherapy as a primary treatment<br/> <b>Setting:</b> specialised hospital<br/> <b>Intervention:</b> extended‐field radiotherapy<br/> <b>Comparison:</b> pelvic radiotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pelvic radiotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with extended‐field radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.67</b><br/> (0.48 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HR was calculated, assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Para‐aortic lymph node recurrence</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> <p>(23 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b> </p> <p>(0.18 to 0.70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.92</b><br/> (0.69 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way, HR was calculated, assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>357 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000<br/> (282 to 503) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/> (0.79 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>776<br/> (2 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="#CD012301-sec-0146">Differences between protocol and review</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a wide 95% confidence interval.<br/> <sup>b</sup>Downgraded one level due to wide confidence intervals crossing the line of no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012301-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Extended‐field radiotherapy compared to pelvic chemoradiotherapy for locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Extended‐field radiotherapy versus pelvic CRT for locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant:</b> women with locally advanced cervical cancer undergoing radiotherapy as a primary treatment<br/> <b>Setting:</b> specialised hospital<br/> <b>Intervention:</b> extended‐field radiotherapy<br/> <b>Comparison:</b> pelvic CRT </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pelvic chemoradiotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with extended‐field radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall surviva</b>l </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.50</b><br/> (0.39 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HRs are calculated, assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Para‐aortic lymph node recurrence</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (19 to 92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b><br/> (0.20 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.52</b><br/> (0.37 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HRs are calculated, assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>646 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (13 to 71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.05</b><br/> (0.02 to 0.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>388<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Late adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000<br/> (122 to 285) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/> (0.69 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision, as indicated by a 95% CI.<br/> <sup>b</sup>Downgraded two levels level due to serious imprecision: wide 95% CI with few events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012301-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Extended‐field chemoradiotherapy compared to pelvic chemoradiotherapy for locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Extended‐field CRT versus pelvic CRT for locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant:</b> women with locally advanced cervical cancer undergoing CRT as a primary treatment<br/> <b>Setting:</b> specialised hospital<br/> <b>Intervention:</b> extended‐field CRT<br/> <b>Comparison:</b> pelvic CRT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pelvic CRT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with extended‐field CRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.37</b><br/> (0.14 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HRs are calculated, assumed, and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Para‐aortic lymph node recurrence</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (3 to 214) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.19</b><br/> (0.02 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.25</b><br/> (0.07 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HRs are calculated, assumed and corresponding risks were not estimated </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/> (17 to 366) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/> (0.20 to 4.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Late adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (2 to 405) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/> (0.06 to 14.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CRT:</b> chemoradiotherapy; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias: the included study had a high risk of bias in three key domains assessed.<br/> <sup>b</sup>Downgraded two levels due to serious imprecision: small sample size and few events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012301-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012301-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012301-sec-0153">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012301-sec-0037"></div> <section id="CD012301-sec-0038"> <h3 class="title" id="CD012301-sec-0038">Description of the condition</h3> <p>Cervical cancer is the most common gynaecological cancer affecting women worldwide, with an estimated 528,000 new cases, and 266,000 cervical cancer deaths, globally in 2012 (<a href="./references#CD012301-bbs2-0026" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 11, 2013. Lyon, France: International Agency for Research on Cancer, Available from: globocan.iarc.fr. ">GLOBOCAN 2012</a>)<i>.</i> Approximately 70% of all cervical cancer cases, and almost 90% of cervical cancer‐related deaths, occur in low‐income countries. The high death rate among women residing in low‐income countries is because most women present with advanced disease (<a href="./references#CD012301-bbs2-0048" title="PisaniP , ParkinDM , BrayF , FerlayJ . Estimates of the worldwide mortality from 25 cancers in 1990. International Journal of Cancer1999;83(1):18‐29. ">Pisani 1999</a>). A woman's risk of developing cervical cancer before the age of 75 years is estimated to range from 0.9% in high‐income to 1.9% in low‐income countries (<a href="./references#CD012301-bbs2-0032" title="JemalA , BrayF , Center MM, FerlayJ , WardE , FormanD . Global cancer statistics. CA: A Cancer Journal for Clinicians2011;61(2):69‐90. ">Jemal 2011</a>)<i>.</i> This discrepancy in the incidence, risk, and stage at diagnosis between high and low‐income countries is due to lack of access to effective screening programmes that facilitate early diagnosis and treatment. </p> <p>A summary of the International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer is displayed in <a href="./appendices#CD012301-sec-0136">Appendix 1</a> (<a href="./references#CD012301-bbs2-0025" title="FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. International Journal of Gynaecology &amp; Obstetrics2014;125(2):97‐8. ">FIGO Committee 2014</a>). Women with FIGO stage IA1 are normally treated with local excision or simple hysterectomy (surgery to remove the uterus and the neck of the uterus). FIGO stage IA2 to IB1 cervical cancers have an increased risk of pelvic lymph node involvement (3.4% to 15.3%) (<a href="./references#CD012301-bbs2-0039" title="MahawerawatS , CharoenkwanK , SrisomboonJ , KhunamornpongS , SuprasertP , Sae‐TengCT . Surgical outcomes of patients with stage IA2 cervical cancer treated with radical hysterectomy. Asian Pacific Journal of Cancer Prevention2013;14(9):5375‐8. ">Mahawerawat 2013</a>; <a href="./references#CD012301-bbs2-0054" title="SakuragiN , SatohC , TakedaN , HareyamaH , TakedaM , YamamotoR , et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and. Cancer1999;85(7):1547‐54. ">Sakuragi 1999</a>; <a href="./references#CD012301-bbs2-0059" title="SpirtosNM , EisenkopSM , SchlaerthJB , BallonSC . Laparoscopic radical hysterectomy (type III) with aortic and pelvic lymphadenectomy in patients with stage I cervical cancer: surgical morbidity and intermediate follow‐up. American Journal of Obstetrics &amp; Gynecology2002;187(2):340‐8. ">Spirtos 2002</a>; <a href="./references#CD012301-bbs2-0062" title="SuprasertP , SrisomboonJ , CharoenkwanK , SiriareeS , CheewakriangkraiC , KietpeerakoolC , et al. Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer. Journal of Obstetrics and Gynaecology2010;30(3):294‐8. ">Suprasert 2010</a>), and are usually treated with radical hysterectomy (the removal of the uterus, the cervix, the upper part of the vagina, and the tissues around the cervix), and pelvic lymph node dissection. However, treatment outcomes of pelvic radiotherapy (RT) are comparable to those of women who undergo surgical treatment (<a href="./references#CD012301-bbs2-0035" title="LandoniF , ManeoA , ColomboA , PlacaF , MilaniR , PeregoP , et al. Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet1997;350(9077):535‐40. ">Landoni 1997</a>). Therefore, decision‐making for early‐stage cervical cancer should be tailored based on individual patient characteristics, weighing up the risks of surgery with the longer‐term risks of radical RT. Pelvic RT was the principal treatment for more advanced cervical cancer, since the rate of positive pelvic lymph nodes is higher (22.7% to 71.4%) (<a href="./references#CD012301-bbs2-0040" title="MarnitzS , KöhlerC , RothC , FüllerJ , HinkelbeinW , SchneiderA . Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer?. Gynecologic Oncology2005;99(3):536‐44. ">Marnitz 2005</a>; <a href="./references#CD012301-bbs2-0054" title="SakuragiN , SatohC , TakedaN , HareyamaH , TakedaM , YamamotoR , et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and. Cancer1999;85(7):1547‐54. ">Sakuragi 1999</a>; <a href="./references#CD012301-bbs2-0060" title="SrisomboonJ , KietpeerakoolC , SuprasertP , ManopanyaM , SiriareeS , CharoenkwanK , et al. Survival and prognostic factors comparing stage IB 1 versus stage IB 2 cervical cancer treated with primary radical hysterectomy. Asian Pacific Journal of Cancer Prevention2011;12(7):1753‐6. ">Srisomboon 2011</a>; <a href="./references#CD012301-bbs2-0062" title="SuprasertP , SrisomboonJ , CharoenkwanK , SiriareeS , CheewakriangkraiC , KietpeerakoolC , et al. Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer. Journal of Obstetrics and Gynaecology2010;30(3):294‐8. ">Suprasert 2010</a>), although some clinicians recommend extended radical hysterectomy for locally advanced disease (<a href="./references#CD012301-bbs2-0031" title="HöckelM . Laterally extended endopelvic resection (LEER) – principles and practice. Gynecologic Oncology2008;111(2 Suppl):S13‐7. ">Höckel 2008</a>). </p> <p>Randomised controlled trial (RCT) data demonstrated that giving chemotherapy at the same time as pelvic RT as a radiosensitiser, or the so‐called 'concurrent chemoradiation' or chemoradiotherapy (CRT) significantly improved the rates of local and distant disease control for women with all stages of cervical cancer compared to RT alone (<a href="./references#CD012301-bbs2-0033" title="KeysHM , BundyBN , StehmanFB , MuderspachLI , ChafeWE , SuggsCL , et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New England Journal of Medicine1999;340(15):1154‐61. ">Keys 1999</a>; <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>; <a href="./references#CD012301-bbs2-0046" title="PetersWA , LuiPY , BarrettRJ , StockRJ , MonkBJ , BerekJS , et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage cancer of the cervix. Journal of Clinical Oncology2000;18(8):1606‐13. ">Peters 2000</a>; <a href="./references#CD012301-bbs2-0051" title="RosePG , BundyBN , WatkinsEB , ThigpenT , DeppeG , MaimanMA , et al. Concurrent cisplatin‐based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine1999;340(15):1144‐53. ">Rose 1999</a>; <a href="./references#CD012301-bbs2-0065" title="WhitneyCW , SauseW , BundyBN , MalfetanoJH , HanniganEV , FowlerWC , et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea in stage IIB/IVA carcinoma of the cervix. Journal of Clinical Oncology1999;17(5):1339‐48. ">Whitney 1999</a>). Pelvic concurrent CRT has been recommended as the treatment of choice instead of pelvic RT alone in locally advanced cervical cancer, if clinically feasible (<a href="./references#CD012301-bbs2-0043" title="National Cancer Institute. NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival, 1999. www.nih.gov/news/pr/feb99/nci22.htm (accessed prior to 20 October 2018). ">National Cancer Institute 1999</a>). One Cochrane Review also endorsed the use of pelvic CRT versus pelvic RT alone for women with cervical cancer based on evidence obtained from individual patient data meta‐analysis (<a href="./references#CD012301-bbs2-0017" title="Chemoradiotherapy for Cervical Cancer Meta‐analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta‐analysis. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD008285] ">CCCMAC 2010</a>). </p> </section> <section id="CD012301-sec-0039"> <h3 class="title" id="CD012301-sec-0039">Description of the intervention</h3> <p>Conventionally, whole pelvis external‐beam RT treatment field covers the space between L4 (fourth lumbar spine) to L5 (fifth lumbar spine) to the mid of pubis, or to a line 4 cm below the most distal vaginal or cervical site of disease. Lateral fields are designed to encompass S3 (third sacral spine) posteriorly, with a margin of at least 3 cm from the primary cervical tumour. The RT schedule is about 1.6 Gy to 2.0 Gy (unit of irradiation dose) per day, five days per week, with a total radiation dose of 45 Gy to 50 Gy. The prescribed dose is delivered to the mid‐depth on the central axis of the beams. Intracavitary brachytherapy is performed after the completion of pelvic RT and a total cumulative dose to point A is at least 80 Gy (<a href="./references#CD012301-bbs2-0023" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. ">Eifel 2004</a>; <a href="./references#CD012301-bbs2-0038" title="LimK , SmallWJr , PortelanceL , CreutzbergC , Jürgenliemk‐SchulzIM , MundtA , et al. Gyn IMRT Consortium. Consensus guidelines for delineation of clinical target volume for intensity‐modulated pelvic radiotherapy for the definitive treatment of cervix cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(2):348‐55. ">Lim 2011</a>; <a href="./references#CD012301-bbs2-0052" title="RotmanM , MoonS , JohnM , ChoiK , SallS . Extended field para‐aortic radiation in cervical carcinoma: the case for prophylactic treatment. International Journal of Radiation Oncology, Biology, Physics1978;4(9‐10):795‐9. ">Rotman 1978</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>). </p> <p>Extended‐field or para‐aortic RT is the extension of whole pelvis external‐beam RT to also cover the para‐aortic lymph nodes (the nodes lying adjacent to the aorta and vena cava, the major vessels in the mid and upper abdomen). This additional RT is delivered in the same setting with the conventional whole pelvis external‐beam RT. The RT schedule and total dose of the two interventions are the same, but the extended‐field RT covers a wider area (<a href="./references#CD012301-bbs2-0023" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. ">Eifel 2004</a>; <a href="./references#CD012301-bbs2-0052" title="RotmanM , MoonS , JohnM , ChoiK , SallS . Extended field para‐aortic radiation in cervical carcinoma: the case for prophylactic treatment. International Journal of Radiation Oncology, Biology, Physics1978;4(9‐10):795‐9. ">Rotman 1978</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>). </p> <p>Severe acute and late morbidities (adverse effects and complications of treatment) seem to be fundamental reasons limiting the use of extended‐field RT for cervical cancer, particularly among women receiving CRT. Severe acute toxicities in women who had undergone extended‐field RT with concomitant chemotherapy occur at approximately 33% to 80% and severe late toxicities (grade 3 or higher) occur in 10% to 15% (<a href="./references#CD012301-bbs2-0034" title="KimYS , KimJH , AhnSD , LeeSW , ShinSS , NamJH , et al. High‐dose extended‐field irradiation and high‐dose‐rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para‐aortic lymph nodes. International Journal of Radiation Oncology, Biology, Physics2009;74(5):1522‐8. ">Kim 2009</a>; <a href="./references#CD012301-bbs2-0010" title="SoodBM , GorlaGR , GargM , AndersonPS , FieldsAL , RunowiczCD , et al. Extended‐field radiotherapy and high‐dose‐rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy. Cancer2003;97(7):1781‐8. ">Sood 2003</a>; <a href="./references#CD012301-bbs2-0013" title="VariaMA , BundyBN , DeppeG , MannelR , AveretteHE , RosePG , et al. Cervical carcinoma metastatic to para‐aortic nodes: extended field radiation therapy with concomitant 5‐fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. International Journal of Radiation Oncology, Biology, Physics1998;42(5):1015‐23. ">Varia 1998</a>). Approximately 10% of women receiving extended‐field RT develop severe acute toxicities and 6% of women develop severe late toxicities, following extended‐field RT alone (<a href="./references#CD012301-bbs2-0010" title="SoodBM , GorlaGR , GargM , AndersonPS , FieldsAL , RunowiczCD , et al. Extended‐field radiotherapy and high‐dose‐rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy. Cancer2003;97(7):1781‐8. ">Sood 2003</a>). </p> </section> <section id="CD012301-sec-0040"> <h3 class="title" id="CD012301-sec-0040">How the intervention might work</h3> <p>Occult para‐aortic lymph node disease can occur in women thought to have locally advanced cervical cancer, which is confined to the pelvis. From a previous literature review, which was undertaken to evaluate the impact of pretreatment surgical para‐aortic lymph node staging on treatment outcomes of cervical cancer, para‐aortic lymph node metastasis were noted in 11% of women with stage I disease, 13% to16% with stage II, 29% with stage III, and 36% with stage IVA (<a href="./references#CD012301-bbs2-0058" title="SmitsRM , ZusterzeelPL , BekkersRL . Pretreatment retroperitoneal para‐aortic lymph node staging in advanced cervical cancer: a review. International Journal of Gynecological Cancer2014;24(6):973‐83. ">Smits 2014</a>). In one review of the literature, despite having normal findings on positron emission tomography (PET) or positron emission tomography‐computed tomography (PET‐CT), 4% to 15% of women thought to have negative para‐aortic lymph node on PET and PET‐CT had para‐aortic lymph node metastasis (<a href="./references#CD012301-bbs2-0058" title="SmitsRM , ZusterzeelPL , BekkersRL . Pretreatment retroperitoneal para‐aortic lymph node staging in advanced cervical cancer: a review. International Journal of Gynecological Cancer2014;24(6):973‐83. ">Smits 2014</a>). </p> <p>Standard radical pelvic RT is likely to be inadequate for women with para‐aortic lymph node metastasis, since the para‐aortic area is outside of standard fields of traditional pelvic RT techniques. Para‐aortic lymph node recurrence is a frequent cause of extrapelvic failure among women with locally advanced cervical cancer who had undergone the standard technique of pelvic RT (21.6% to 57.1%) (<a href="./references#CD012301-bbs2-0030" title="HongJH , TsaiCS , LaiCH , ChangTC , WangCC , ChouHH , et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. International Journal of Radiation Oncology, Biology, Physics2004;60(1):249‐57. ">Hong 2004</a>; <a href="./references#CD012301-bbs2-0055" title="SakuraiH , MitsuhashiN , TakahashiM , AkimotoT , MuramatsuH , IshikawaH , et al. Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods, and prognosis. International Journal of Radiation Oncology, Biology, Physics2001;50(5):1136‐44. ">Sakurai 2001</a>). Even in the era of concomitant CRT, para‐aortic lymph node metastasis has been noted in approximately 7% to 15% of women undergoing concomitant CRT for cervical cancer (<a href="./references#CD012301-bbs2-0023" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. ">Eifel 2004</a>; <a href="./references#CD012301-bbs2-0045" title="PearceyR , BrundageM , DrouinP , JeffreyJ , JohnstonD , LukkaH , et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. Journal of Clinical Oncology2002;20(4):966‐72. ">Pearcey 2002</a>; <a href="./references#CD012301-bbs2-0063" title="ToitaT , KitagawaR , HamanoT , UmayaharaK , HirashimaY , AokiY , et al. Phase II study of concurrent chemoradiotherapy with high‐dose‐rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecologic Oncology2012;126(2):211‐6. ">Toita 2012</a>). </p> <p>Previous studies have observed that extended‐field RT prolonged the survival of women with endometrial cancer (<a href="./references#CD012301-bbs2-0050" title="RosePG , ChaSD , TakWK , FitzgeraldT , RealeF , HunterRE . Radiation therapy for surgically proven para‐aortic node metastasis in endometrial carcinoma. International Journal of Radiation Oncology, Biology, Physics1992;24(2):229‐33. ">Rose 1992</a>), and cervical cancer (<a href="./references#CD012301-bbs2-0041" title="MarnitzS , SchramJ , BudachV , SackererI , VercellinoGF , SehouliJ , et al. Extended field chemoradiation for cervical cancer patients with histologically proven para‐aortic lymph node metastases after laparoscopic lymphadenectomy. Strahlentherapie und Onkologie2015;191(5):421‐8. ">Marnitz 2015</a>; <a href="./references#CD012301-bbs2-0013" title="VariaMA , BundyBN , DeppeG , MannelR , AveretteHE , RosePG , et al. Cervical carcinoma metastatic to para‐aortic nodes: extended field radiation therapy with concomitant 5‐fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. International Journal of Radiation Oncology, Biology, Physics1998;42(5):1015‐23. ">Varia 1998</a>) who had para‐aortic lymph node metastasis. In addition, prophylaxis extended‐field RT to the para‐aortic region improved overall survival in women with cervical cancer (<a href="./references#CD012301-bbs2-0053" title="RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1995</a>). Based on these findings, delivering extended‐field RT to cover para‐aortic regions aimed at eliminating unrecognised metastatic lesions might be effective for reducing treatment failure at this region and thus improving treatment outcomes of women with cervical cancer. </p> </section> <section id="CD012301-sec-0041"> <h3 class="title" id="CD012301-sec-0041">Why it is important to do this review</h3> <p>The prognosis for women with recurrent cervical cancer is poor and para‐aortic lymph node recurrence is one of the most common sites of treatment failure in women with cervical cancer (<a href="./references#CD012301-bbs2-0030" title="HongJH , TsaiCS , LaiCH , ChangTC , WangCC , ChouHH , et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. International Journal of Radiation Oncology, Biology, Physics2004;60(1):249‐57. ">Hong 2004</a>; <a href="./references#CD012301-bbs2-0055" title="SakuraiH , MitsuhashiN , TakahashiM , AkimotoT , MuramatsuH , IshikawaH , et al. Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods, and prognosis. International Journal of Radiation Oncology, Biology, Physics2001;50(5):1136‐44. ">Sakurai 2001</a>). However, there is significant morbidity from extended‐field RT (<a href="./references#CD012301-bbs2-0034" title="KimYS , KimJH , AhnSD , LeeSW , ShinSS , NamJH , et al. High‐dose extended‐field irradiation and high‐dose‐rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para‐aortic lymph nodes. International Journal of Radiation Oncology, Biology, Physics2009;74(5):1522‐8. ">Kim 2009</a>; <a href="./references#CD012301-bbs2-0010" title="SoodBM , GorlaGR , GargM , AndersonPS , FieldsAL , RunowiczCD , et al. Extended‐field radiotherapy and high‐dose‐rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy. Cancer2003;97(7):1781‐8. ">Sood 2003</a>; <a href="./references#CD012301-bbs2-0013" title="VariaMA , BundyBN , DeppeG , MannelR , AveretteHE , RosePG , et al. Cervical carcinoma metastatic to para‐aortic nodes: extended field radiation therapy with concomitant 5‐fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. International Journal of Radiation Oncology, Biology, Physics1998;42(5):1015‐23. ">Varia 1998</a>). Evidence for an effective strategy in reducing para‐aortic lymph node recurrence is therefore required to establish whether extended‐field RT may decrease the risk of para‐aortic recurrence. To date there has been no systematic review evaluating the impact of extended‐field RT on the treatment outcomes of women with locally advanced cervical cancer. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012301-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012301-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012301-sec-0158">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012301-sec-0042"></div> <p>To evaluate the effectiveness and toxicity of extended‐field radiotherapy in women undergoing first‐line treatment for locally advanced cervical cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012301-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012301-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012301-sec-0159">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012301-sec-0043"></div> <section id="CD012301-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012301-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included RCTs. We excluded quasi‐randomised trials as these may have been subject to bias. </p> </section> <section id="CD012301-sec-0046"> <h4 class="title">Types of participants</h4> <p>Women aged 18 years or older undergoing first‐line treatment for locally advanced cervical cancer. Cervical cancers with the largest diameter of 4 cm or larger or FIGO stage IIB to IVA (or both) were considered locally advanced. Details of the FIGO staging classification of cervical cancer are shown in <a href="./appendices#CD012301-sec-0136">Appendix 1</a> (<a href="./references#CD012301-bbs2-0025" title="FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. International Journal of Gynaecology &amp; Obstetrics2014;125(2):97‐8. ">FIGO Committee 2014</a>). </p> </section> <section id="CD012301-sec-0047"> <h4 class="title">Types of interventions</h4> <p>We compared extended‐field versus standard radical pelvic RT as follows:</p> <p> <ul id="CD012301-list-0001"> <li> <p>extended‐field RT versus pelvic RT alone;</p> </li> <li> <p>extended‐field RT versus pelvic CRT;</p> </li> <li> <p>extended‐field CRT versus pelvic CRT.</p> </li> </ul> </p> </section> <section id="CD012301-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD012301-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012301-list-0002"> <li> <p>Overall survival (OS): survival until death from all causes. Survival was assessed from the time when women were enrolled in the study. </p> </li> <li> <p>Para‐aortic lymph node recurrence: any relapse or persistent disease at the para‐aortic region. </p> </li> </ul> </p> </section> <section id="CD012301-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012301-list-0003"> <li> <p>Progression‐free survival (PFS) or disease progression: survival until appearance of a new lesion. Survival was assessed from the time when women were enrolled in the study. </p> </li> <li> <p>Non‐para‐aortic recurrence: recurrent disease other than the para‐aortic region was classified as locoregional and distant recurrences. </p> </li> <li> <p>Adverse events: which were classified as:</p> <ul id="CD012301-list-0004"> <li> <p>acute complications including digestive complications (e.g. nausea/vomiting, diarrhoea); urological complications (e.g. cystitis); haematological complications (e.g. anaemia, leukopenia, neutropenia, and thrombocytopenia); and cardiovascular and thromboembolic complications (e.g. myocardial infarction, arterial thrombosis, venous thrombosis, pulmonary embolism); </p> </li> <li> <p>late complications including digestive complications (e.g. proctitis, sigmoiditis, intestinal obstruction, and fistular formation); and urological complications (e.g. chronic cystitis, incontinence, ureteral stenosis, and fistula) (<a href="./references#CD012301-bbs2-0020" title="CoxJD , StetzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal Of Radiation Oncology Biology Physics1995;31(5):1341‐6. ">Cox 1995</a>). </p> </li> </ul> </li> <li> <p>Quality of life: using validated scales (i.e. European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐CX24; <a href="./references#CD012301-bbs2-0027" title="GreimelER , Kuljanic VlasicK , WaldenstromAC , DuricVM , JensenPT , SingerS , et al. The European Organization for Research and Treatment of Cancer (EORTC) Quality‐of‐Life questionnaire cervical cancer module: EORTC QLQ‐CX24. Cancer2006;107(8):1812‐22. ">Greimel 2006</a>). </p> </li> <li> <p>Cost‐effectiveness: using a scale that was validated and reported in a peer‐reviewed publication (i.e. European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO‐MCBS; <a href="./references#CD012301-bbs2-0018" title="ChernyNI , SullivanR , DafniU , KerstJM , SobreroA , ZielinskiC , et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti‐cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO‐MCBS). Annals of Oncology2015;26(8):1547‐73. ">Cherny 2015</a>). </p> </li> </ul> </p> <p>We presented a 'Summary of findings' tables reporting the following outcomes listed in order of priority (see <a href="#CD012301-sec-0065">Data synthesis</a>). </p> <p> <ul id="CD012301-list-0005"> <li> <p>Overall survival.</p> </li> <li> <p>Para‐aortic lymph node recurrence.</p> </li> <li> <p>Progression‐free survival.</p> </li> <li> <p>Non‐para‐aortic recurrence.</p> </li> <li> <p>Adverse events.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Cost‐effectiveness.</p> </li> </ul> </p> </section> </section> </section> <section id="CD012301-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012301-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD012301-list-0006"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 7) in the Cochrane Library; </p> </li> <li> <p>MEDLINE via Ovid (1946 to August week 4, 2018);</p> </li> <li> <p>Embase via Ovid (1980 to 2018, week 35).</p> </li> </ul> </p> <p><a href="./appendices#CD012301-sec-0137">Appendix 2</a>; <a href="./appendices#CD012301-sec-0138">Appendix 3</a>; <a href="./appendices#CD012301-sec-0139">Appendix 4</a> display the search strategies for CENTRAL, MEDLINE, and Embase. </p> </section> <section id="CD012301-sec-0053"> <h4 class="title">Searching other resources</h4> <section id="CD012301-sec-0054"> <h5 class="title">Ongoing studies and grey literature</h5> <p>We searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) and <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> to identify any ongoing trials. If we had identified ongoing trials that had not been published, we planned to approach the principal investigators, and major co‐operative groups active in this area, to ask for relevant data<i>.</i> </p> <p>We searched the following databases for grey literature: Open‐Grey (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>) and Index to theses (<a href="http://%20ProQuest%20Dissertations%20%26%20Theses:%20UK%20%26%20Ireland" target="_blank">ProQuest Dissertations &amp; Theses: UK &amp; Ireland</a>). </p> </section> <section id="CD012301-sec-0055"> <h5 class="title">Handsearching</h5> <p>We handsearched the citation lists of included studies and key textbooks, and contacted experts in the field to identify further reports of trials. We also handsearched the reports of conferences in the following sources. </p> <p> <ul id="CD012301-list-0007"> <li> <p>Annual Meeting of the American Society of Gynecologic Oncology (ASGO).</p> </li> <li> <p>Annual Meeting of the American Society of Radiation Oncology (ASTRO).</p> </li> <li> <p>Annual Meeting of European Society of Radiotherapy and Oncology (ESTRO).</p> </li> <li> <p>Annual Meeting of European Society of Medical Oncology (ESMO).</p> </li> <li> <p>Annual Meeting of the American Society of Clinical Oncology (ASCO).</p> </li> <li> <p>Annual Meeting of the British Gynaecological Cancer Society (BGCS).</p> </li> <li> <p>Biennial Meeting of the Asian Society of Gynecologic Oncology (ASGO).</p> </li> <li> <p>Biennial Meeting of Asia and Oceania Federation of Obstetrics and Gynaecology (AOFOG).</p> </li> <li> <p>Biennial Meeting of the European Society of Gynaecological Oncology (ESGO).</p> </li> <li> <p>Biennial Meeting of the International Gynecologic Cancer Society (IGCS).</p> </li> </ul> </p> </section> </section> </section> <section id="CD012301-sec-0056"> <h3 class="title" id="CD012301-sec-0056">Data collection and analysis</h3> <section id="CD012301-sec-0057"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to a reference management database (<a href="./references#CD012301-bbs2-0024" title="Thomas Reuters. Endnote Version X7. New York: Thomas Reuters, 2015. ">Endnote</a>). After removal of duplicates, we transferred these data to Covidence (<a href="https://www.covidence.org" target="_blank">www.covidence.org</a>). Two review authors (KT and NS) independently examined the remaining references. We excluded studies that clearly did not meet the inclusion criteria, and we obtained copies of the full‐text of potentially relevant references. Two review authors (KT and NS) independently assessed the eligibility of the retrieved reports/publications. We resolved any disagreements through discussion or, when required, we consulted a third review author (CK). We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We used the details regarding the selection process in <a href="./references#CD012301-bbs2-0019" title="Covidence systematic reviewsoftware . Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org. ">Covidence 2018</a> to complete a PRISMA flow diagram and <a href="./references#CD012301-sec-0152" title="">Characteristics of excluded studies</a> table (<a href="./references#CD012301-bbs2-0037" title="LiberatiA , AltmanD , TetzlaffJ , MulrowC , GotzscheP , IoannidisJ , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ2009;339:b2700. ">Liberati 2009</a>). </p> </section> <section id="CD012301-sec-0058"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (KT and NS) independently extracted study characteristics and outcome data from included studies using <a href="./references#CD012301-bbs2-0019" title="Covidence systematic reviewsoftware . Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org. ">Covidence 2018</a>. We noted in the <a href="./references#CD012301-sec-0151" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by consensus or by involving a third review author (PL or CK). A second review author (CK) checked study characteristics for accuracy against the trial report. </p> <p>For included studies, we extracted the following data using a piloted data collection form. </p> <p> <ul id="CD012301-list-0008"> <li> <p>Author, year of publication, and journal citation (including language).</p> </li> <li> <p>Country.</p> </li> <li> <p>Setting.</p> </li> <li> <p>Inclusion and exclusion criteria.</p> </li> <li> <p>Study methodology.</p> </li> <li> <p>Study population and characteristics:</p> <ul id="CD012301-list-0009"> <li> <p>total number enrolled;</p> </li> <li> <p>participant characteristics;</p> </li> <li> <p>age;</p> </li> <li> <p>co morbidities;</p> </li> <li> <p>other baseline characteristics;</p> </li> <li> <p>FIGO stage of cervical cancer;</p> </li> <li> <p>tumour size (largest diameter);</p> </li> <li> <p>histopathological type of cervical cancer;</p> </li> <li> <p>status of para‐aortic lymph node.</p> </li> </ul> </li> </ul> <ul id="CD012301-list-0010"> <li> <p>Intervention details:</p> <ul id="CD012301-list-0011"> <li> <p>any regimens of pelvic RT or CRT plus extended‐field RT;</p> </li> <li> <p>RT technique;</p> </li> <li> <p>dose;</p> </li> <li> <p>duration;</p> </li> <li> <p>schedule.</p> </li> </ul> </li> <li> <p>Comparison:</p> <ul id="CD012301-list-0012"> <li> <p>any regimens of pelvic RT or CRT.</p> </li> </ul> </li> <li> <p>Risk of bias in study (see below).</p> </li> <li> <p>Duration of follow‐up.</p> </li> <li> <p>Outcomes: for each outcome, we extracted the outcome definition and unit of measurement. For adjusted estimates, we planned to record variables adjusted for in analyses. </p> </li> <li> <p>Results: we extracted the number of participants allocated to each intervention group, the total number analysed for each outcome, and the missing participants. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Results were extracted as follows.</p> <p> <ul id="CD012301-list-0013"> <li> <p>For time to event data (survival and disease progression), we extracted the log of the hazard ratio [log(HR)] and its standard error (SE) from trial reports. If these were not reported, we estimated the log (HR) and its SE using the methods of <a href="./references#CD012301-bbs2-0044" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>. </p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events or deaths, if it was not possible to use the HR), we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint, in order to estimate a risk ratio (RR) with 95% confidence interval (CI). </p> </li> </ul> </p> <p>Where possible, all data extracted were those relevant to an intention‐to‐treat analysis, in which participants were analysed in groups to which they were assigned. </p> </section> <section id="CD012301-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed and reported on the methodological quality and risk of bias in included studies in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012301-bbs2-0029" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), which recommends the explicit reporting of the following individual elements for RCTs. </p> <p> <ul id="CD012301-list-0014"> <li> <p>Selection bias: random sequence generation and allocation concealment.</p> </li> <li> <p>Performance bias: blinding of participants and personnel (participants and treatment providers). </p> </li> <li> <p>Detection bias: blinding of outcome assessment.</p> </li> <li> <p>Attrition bias: incomplete outcome data.</p> </li> <li> <p>Reporting bias: selective reporting of outcomes.</p> </li> <li> <p>Other possible bias.</p> </li> </ul> </p> <p>Two review authors (NS and CK) independently applied the Cochrane 'Risk of bias' tool and resolved differences by discussion or by appeal to a third review author (PL). We judged each item as being at high, low, or unclear risk of bias as set out in the criteria displayed in <a href="./appendices#CD012301-sec-0140">Appendix 5</a> (<a href="./references#CD012301-bbs2-0029" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We provided a quote from the study report or a statement as justification for the judgement for each item (or both a quote and statement) in the 'Risk of bias' table. We summarised results in both a 'Risk of bias' graph and a 'Risk of bias' summary. When interpreting treatment effects and meta‐analyses, we took into account the risk of bias for the studies that contributed to that outcome. Where information on risk of bias related to unpublished data or correspondence with a trial authors, we noted this in the table. </p> </section> <section id="CD012301-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment.</p> <p> <ul id="CD012301-list-0015"> <li> <p>For survival outcomes (e.g. OS and PFS), we used HR and 95% CI.</p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events, recurrences, and death), we analysed data based on the number of events and the number of people assessed in the intervention and comparison groups. We planned to use these to calculate the RR and 95% CI. </p> </li> <li> <p>For continuous outcomes (e.g. quality of life and cost‐effectiveness measures), we planned to analyse data based on the mean, standard deviation (SD), and number of people assessed for both the intervention and comparison groups to calculate mean difference (MD) between treatment arms with a 95% CI. If the MD was reported without individual group data, we planned to use this to report the study results. If studies measured the same outcome using different tools, we planned to calculate the standardised mean difference (SMD) and 95% CI using the inverse variance method. </p> </li> </ul> </p> </section> <section id="CD012301-sec-0061"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to include studies where individual participants were randomised and cluster‐randomised studies. For studies that used a cluster‐randomised design but did not have any information related to the design effect, we planned to estimate the design effect based on a fairly large assumed intracluster correlation of 0.10. We planned to base this assumption by analogy on studies about implementation research (<a href="./references#CD012301-bbs2-0016" title="CampbellMJ . Cluster randomized trials in general (family) practice research. Statistical Methods in Medical Research2000;9(2):81‐94. ">Campbell 2000</a>; <a href="./references#CD012301-bbs2-0064" title="UkoumunneOC , GullifordMC , ChinnS , SterneJA , BurneyPG . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999;3(5):iii‐92. ">Ukoumunne 1999</a>). We intended to follow the methods stated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for determining the calculations (<a href="./references#CD012301-bbs2-0029" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). In a study with multiple intervention groups, where possible, we planned to combine all relevant experimental intervention groups into a single group to create a single pair‐wise comparison (<a href="./references#CD012301-bbs2-0029" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>)<i>.</i> </p> <p>Only studies that randomised individual participants into one of two comparison groups met our inclusion criteria. There was no requirement to review unit of analysis issues. This may be required in updates of this review, should additional studies become available. </p> </section> <section id="CD012301-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing outcome data for any of the outcomes.</p> </section> <section id="CD012301-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies by visually inspecting forest plots, estimating the percentage of heterogeneity (I² statistic) and Chi² test between trials that could not be ascribed to sampling variation (<a href="./references#CD012301-bbs2-0028" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>; <a href="./references#CD012301-bbs2-0029" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), and performing a formal statistical test of the significance of identified heterogeneity (<a href="./references#CD012301-bbs2-0021" title="DeeksJ , AltmanD , BradburnM . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , Davey SmithG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001. ">Deeks 2001</a>), and, where possible, by subgroup analyses. If there was evidence of substantial heterogeneity (I² greater than 60%), we investigated and reported the possible reasons for this. </p> </section> <section id="CD012301-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to construct funnel plots to determine the possibility of publication bias. In future updates of this review, we will construct funnel plots corresponding to meta‐analysis of the primary outcomes to assess the potential for small‐study effects such as publication bias, if we identify more than 10 studies. We plan to assess funnel plot asymmetry visually (<a href="./references#CD012301-bbs2-0061" title="SterneJ , SuttonA , LoannidisJ , TerrinN , JonesD , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). </p> <p>We did not determine the potential of reporting bias, as there were too few studies available for this review. </p> </section> <section id="CD012301-sec-0065"> <h4 class="title">Data synthesis</h4> <p>We pooled the results in a meta‐analyses. We used the random‐effects model with inverse variance weighting for all meta‐analyses (<a href="./references#CD012301-bbs2-0022" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). We performed statistical analysis using Review Manager 5 (<a href="./references#CD012301-bbs2-0049" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p> <ul id="CD012301-list-0016"> <li> <p>For time‐to‐event data, we pooled HRs using the generic inverse variance.</p> </li> <li> <p>For dichotomous outcomes, we calculated the RRs for each study and pooled them.</p> </li> <li> <p>For continuous outcomes, we planned to pool the MDs between the treatment arms, if trials measured the outcome on the same scale; if trials measured the outcome on a different scale, we planned to pool SMDs. </p> </li> </ul> </p> <p>We prepared 'Summary of findings' tables to display the results of the meta‐analysis, based on the methods described in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012301-bbs2-0057" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. ">Schünemann 2011</a>). We presented the results of the meta‐analysis for the outcomes and harms as outlined in the <a href="#CD012301-sec-0048">Types of outcome measures</a> section. If we are unable to pool the results using meta‐analysis methods, we planned to conduct a narrative review of the available results. </p> <section id="CD012301-sec-0066"> <h5 class="title">Main outcomes of 'Summary of findings' tables for assessing the certainty of the evidence</h5> <p>We presented the overall certainty of evidence for each outcome according to the GRADE approach, which takes into account issues relating to internal validity (risk of bias, inconsistency, imprecision, publication bias), and external validity such as directness of results (<a href="./references#CD012301-bbs2-0036" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchünemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;23(2):81. ">Langendam 2013</a>)<i>.</i> We created 'Summary of findings' tables based on the methods described the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012301-bbs2-0029" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) and using <a href="http://gradepro.org/" target="_blank">GRADEpro GDT</a>. We used the GRADE checklist and GRADE Working Group definitions (<a href="./references#CD012301-bbs2-0042" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. ">Meader 2014</a>). We downgraded the evidence from high certainty by one level for serious (or by two for very serious) limitations. See <a href="./full#CD012301-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012301-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012301-tbl-0003">summary of findings Table 3</a>. </p> <p> <ul id="CD012301-list-0017"> <li> <p><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p><b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p><b>Very‐low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> <section id="CD012301-sec-0067"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses for the following factors:</p> <p> <ul id="CD012301-list-0018"> <li> <p>type of treatment (CRT versus RT only);</p> </li> <li> <p>status of para‐aortic lymph node (unknown versus negative on radiological imaging).</p> </li> </ul> </p> <p>However, we did not perform subgroup analysis, as most analyses were based on only one or two included studies. Nevertheless, we acknowledged these factors in the interpretation of review findings. </p> </section> <section id="CD012301-sec-0068"> <h4 class="title">Sensitivity analysis</h4> <p>We were unable to conduct sensitivity analysis because of the small number of studies. If more studies are included in future review updates, we will perform sensitivity analysis to assess the effect of the following factors. </p> <p> <ul id="CD012301-list-0019"> <li> <p>Repeating the analysis excluding unpublished studies, if any.</p> </li> <li> <p>Repeating the analysis excluding studies judged at high or unclear risk of bias for allocation concealment. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012301-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012301-sec-0069"></div> <section id="CD012301-sec-0070"> <h3 class="title">Description of studies</h3> <section id="CD012301-sec-0071"> <h4 class="title">Results of the search</h4> <p>A broad search of the literature databases in August 2018 yielded the following results; CENTRAL (99 references), MEDLINE (115 references), and Embase (159 references). Searching other bases yielded one congress abstract. After deduplication, we screened titles and abstracts of 252 references and excluded 235 that obviously did not meet the review inclusion criteria. The search found no ongoing trials. Of the 17 references that potentially met the review inclusion, we excluded 10 reports after reviewing the full texts (see <a href="./references#CD012301-sec-0152" title="">Characteristics of excluded studies</a> table). <a href="#CD012301-fig-0001">Figure 1</a> shows the PRISMA flow chart for study selection. We included five studies (seven reports). </p> <div class="figure" id="CD012301-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. RCT: randomised controlled trial; RT: radiotherapy." data-id="CD012301-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. RCT: randomised controlled trial; RT: radiotherapy.</p> </div> </div> </div> </section> <section id="CD012301-sec-0072"> <h4 class="title">Included studies</h4> <p>Five studies (seven reports) met the inclusion criteria (<a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>; <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>). <a href="./references#CD012301-bbs2-0053" title="RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1995</a> reported 10‐year treatment results of <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>. <a href="./references#CD012301-bbs2-0023" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. ">Eifel 2004</a> described updated results of <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>. See <a href="./references#CD012301-sec-0151" title="">Characteristics of included studies</a> table for details of each study. </p> <section id="CD012301-sec-0073"> <h5 class="title">Participants</h5> <p><a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a> was a two‐armed parallel RCT conducted by the Radiotherapy Cooperative Group of EORTC from November 1977 to July 1981. Participants were previously 441 untreated women with histologically confirmed carcinoma of the cervix with high risk of subclinical para‐aortic node metastases. Women were considered ineligible if they had para‐aortic lymph node involvement confirmed either by surgery or diagnosed on lymphangiography. </p> <p><a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a> was a two‐armed parallel RCT conducted by the Radiation Therapy Oncology Group (RTOG) from November 1979 to October 1986. This study analysed 335 women who had cervical cancer stage IIB without clinical evidence of para‐aortic nodal involvement or stages IB and IIA with tumour size of 4 cm or greater in lateral dimension. Women were considered eligible if they had no clinical evidence of para‐aortic lymph node metastases. However, approximately one‐third (37%) did not undergo any para‐aortic lymph node evaluation. Of the remaining 63% of participants, 50% were treated by non‐surgical procedures and 13% were treated by surgical procedures. The median follow‐up time was six years. Updated data of this report were subsequently published in <a href="./references#CD012301-bbs2-0053" title="RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1995</a>. </p> <p><a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> conducted an RCT study at University Hospital in Japan between November 1986 and October 1990. Ninety‐three women with cervical carcinoma were randomly allocated for treatment with either pelvic RT or extended‐field RT. Thirty‐six participants received RT as a primary therapy and the remaining 57 participants received RT as an adjuvant treatment following extended radical hysterectomy. Based on the review inclusion criteria, only data obtained from the RT arm in which 18 participants were randomly allocated to each pelvic RT group and extended‐field RT group were extracted for meta‐analyses. </p> <p><a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a> was a two‐armed parallel, RCT conducted by RTOG between 1990 and 1997. Participants were 388 women who had FIGO stages IIB to IVA, squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix or stage IB or IIA of one of these cancers with a tumour diameter of at least 5 cm or biopsy‐confirmed metastasis to pelvic lymph nodes. All participants underwent para‐aortic lymph node evaluation by bipedal lymphangiogram or retroperitoneal surgical exploration. Women who had cancer spreading to para‐aortic lymph nodes were ineligible. Median follow‐up time was 43 months. The results of this study were updated in <a href="./references#CD012301-bbs2-0023" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. ">Eifel 2004</a>. </p> <p><a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a> was a two‐armed parallel, RCT conducted between July 2007 and April 2008. Participants were 74 women with histopathologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma, and radiologically negative para‐aortic lymph node cervical cancer stage IIB to IVA. </p> </section> <section id="CD012301-sec-0074"> <h5 class="title">Interventions</h5> <p><a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; and <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a> compared pelvic RT versus extended‐field RT. </p> <p><a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a> compared pelvic CRT (with fluorouracil and cisplatin concurrent chemotherapy) versus extended‐field RT alone. </p> <p><a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a> compared pelvic CRT (with weekly cisplatin concurrent chemotherapy) versus extended‐field CRT (with weekly cisplatin concurrent chemotherapy). </p> </section> <section id="CD012301-sec-0075"> <h5 class="title">Outcomes</h5> <p><a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a> reported disease‐free survival, rates of locoregional and distant recurrences, and severe adverse events </p> <p><a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>; <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>; and <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>, reported OS, disease‐free survival, rates of locoregional and distant recurrences, and severe adverse events. </p> <p><a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> reported the three‐year cause‐specific survival, rates of locoregional and distant recurrences. The authors reported rate of adverse event but did not state its severity. </p> <p><a href="./references#CD012301-bbs2-0053" title="RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1995</a> updated the results of <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>. In <a href="./references#CD012301-bbs2-0053" title="RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1995</a>, every participant could have been followed up for at least eight years, and 55% of the participants could have been followed up for at least 10 years. </p> <p><a href="./references#CD012301-bbs2-0023" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. ">Eifel 2004</a> reported an updated results of <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>. The median follow‐up time of the early and updated reports was 43 months (<a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>) and 6.6 years (<a href="./references#CD012301-bbs2-0023" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. ">Eifel 2004</a>). </p> <p><a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>; <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0023" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. ">Eifel 2004</a>; and <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a> reported rate of para‐aortic recurrence. </p> <p>None of the studies reported quality of life and cost‐effectiveness.</p> </section> </section> <section id="CD012301-sec-0076"> <h4 class="title">Excluded studies</h4> <p>We excluded seven studies that were not RCTs (<a href="./references#CD012301-bbs2-0006" title="DuXL , ShengXG , JiangT , YuH , YanYF , GaoR , et al. Intensity‐modulated radiation therapy versus para‐aortic field radiotherapy to treat para‐aortic lymph node metastasis in cervical cancer: prospective study. Croatian Medical Journal2010;51(3):229‐36. ">Du 2010</a>; <a href="./references#CD012301-bbs2-0008" title="LiangJA , ChenSW , HungYC , YehLS , ChangWC , LinWC , et al. Low‐dose, prophylactic, extended‐field, intensity‐modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2–IIIB cervical cancer, positive pelvic lymph nodes, and negative para‐aortic lymph nodes. International Journal of Gynecological Cancer2014;24(5):901‐7. ">Liang 2014</a>; <a href="./references#CD012301-bbs2-0010" title="SoodBM , GorlaGR , GargM , AndersonPS , FieldsAL , RunowiczCD , et al. Extended‐field radiotherapy and high‐dose‐rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy. Cancer2003;97(7):1781‐8. ">Sood 2003</a>; <a href="./references#CD012301-bbs2-0012" title="VargoJA , KimH , ChoiS , SukumvanichP , OlawaiyeAB , KelleyJL , et al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node‐positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. International Journal of Radiation Oncology, Biology, Physics2014;90(5):1091‐8. ">Vargo 2014</a>; <a href="./references#CD012301-bbs2-0013" title="VariaMA , BundyBN , DeppeG , MannelR , AveretteHE , RosePG , et al. Cervical carcinoma metastatic to para‐aortic nodes: extended field radiation therapy with concomitant 5‐fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. International Journal of Radiation Oncology, Biology, Physics1998;42(5):1015‐23. ">Varia 1998</a>; <a href="./references#CD012301-bbs2-0014" title="WakatsukiM , KatoS , KiyoharaH , OhnoT , KarasawaK , TamakiT , et al. Clinical trial of prophylactic extended‐field carbon‐ion radiotherapy for locally advanced uterine cervical cancer (protocol 0508). PloS One2015;10(5):e0127587. ">Wakatsuki 2015</a>; <a href="./references#CD012301-bbs2-0015" title="YoonH , ChaJ , KimG , ChungY , KimY . The long‐term follow‐up result of extended field radiation therapy for uterine cervical cancer with positive para‐aortic lymph nodes: does the addition of chemotherapy have survival benefit?. International Journal of Radiation Oncology, Biology, Physics2014;S:479. ">Yoon 2014</a>). </p> <p>We excluded two studies because the interventions applied were not applicable to this review (<a href="./references#CD012301-bbs2-0009" title="LinSY , TsaiCS , ChangYC , NgKK , ChangTC , KaoWH , et al. The role of pretreatment FDG‐PET in treating cervical cancer patients with enlarged pelvic lymph node(s) shown on MRI: a phase 3 randomized trial with long‐term follow‐up. International Journal of Radiation Oncology, Biology, Physics2015;92(3):577‐85. ">Lin 2015</a>; <a href="./references#CD012301-bbs2-0011" title="TsaiCS , LaiCH , ChangTC , YenTC , NgKK , HsuehS , et al. A prospective randomized trial to study the impact of pretreatment FDG‐PET for cervical cancer patients with MRI‐detected positive pelvic but negative para‐aortic lymphadenopathy. International Journal of Radiation Oncology, Biology, Physics2010;76(2):477‐84. ">Tsai 2010</a>). </p> <p>One study divided participants into two comparison groups by the status of CA9 immunohistochemical staining (CA9‐positive and CA9‐negative) and then were randomly allocated to extended‐field RT and pelvic RT arms (<a href="./references#CD012301-bbs2-0007" title="KimJH , KimJY , YoonMS , KimYS , LeeJH , KimHJ , et al. Prophylactic irradiation of para‐aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07‐01): a randomized, open‐label, multicenter, phase 2 trial. Radiotherapy and Oncology2016;120(3):383‐9. ">Kim 2016</a>). This was excluded because the results were reported according to the status of CA9 expression. There were no data available for comparing extended‐field RT and pelvic RT, which was the comparison that this review aimed to evaluate (see <a href="./references#CD012301-sec-0152" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD012301-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD012301-sec-0151" title="">Characteristics of included studies</a> table; <a href="#CD012301-fig-0002">Figure 2</a>; and <a href="#CD012301-fig-0003">Figure 3</a> for full details. </p> <div class="figure" id="CD012301-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012301-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012301-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012301-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012301-sec-0078"> <h4 class="title">Allocation</h4> <p><a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a> stated that the participants were randomised by drawing a sealed envelope which contained computer‐generated random numbers thus indicating a low risk of selection bias. </p> <p><a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a> and <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> did not state the methods of random sequence generation and allocation concealment. Therefore, these two included studies had an unclear risk of selection bias. </p> <p>There was no information regarding the sequence generation process and method applied for allocation concealment provided in <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a> and <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>. By personal communication, however, to Kathryn Winter, Co‐Director, Division of Biostatistics and Science, NRG Oncology SDMC/RTOG and Senior Director of Statistics, American College of Radiology, treatment allocations in either RTOG 7902 (<a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>) or RTOG 9001 (<a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>) were made centrally by the RTOG Statistical Center using an algorithm that implemented a permuted block randomisation scheme (<a href="./references#CD012301-bbs2-0066" title="WinterK . Request for information of published article [personal communication]. Email to: Kathryn Winter 2017 11 August 2017. ">Winter 2017 [pers comm]</a>). Therefore, <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a> and <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a> had low risk of selection bias. </p> </section> <section id="CD012301-sec-0079"> <h4 class="title">Blinding</h4> <p>None of the studies provided statements regarding blinding of participants, personnel, and outcome assessor. Although blinding of participants and personnel is not easily applicable in this study setting, the outcomes of interest, including survival, cancer recurrence, and grade 3 or 4 complications we deemed it unlikely to be affected by lack of blinding of participants and personnel. Therefore, blinding was at a low risk of bias in all included studies. </p> </section> <section id="CD012301-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a> excluded relatively high numbers of participants (28 participants, 27.5%) after randomisation due to incomplete treatment protocol (11 participants), incomplete staging (seven participants), irregular follow‐up (six participants), and social reasons (four participants), leaving only 74 participants for analyses (36 in pelvic CRT group and 38 in extended‐field CRT group). Therefore, <a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a> was at high risk of attrition bias. </p> <p>Other included studies had low percentages of withdrawals and dropouts indicating a low risk of attrition bias (<a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>; see <a href="./references#CD012301-sec-0151" title="">Characteristics of included studies</a> table for the proportion of participants analysed). </p> </section> <section id="CD012301-sec-0081"> <h4 class="title">Selective reporting</h4> <p>None of the included studies reported quality of life and cost‐effectiveness. <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> and <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a> did not report OS, which is an important oncological outcome. <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> did not report the severity of adverse events. So all included studies were at high risk of reporting bias. </p> </section> <section id="CD012301-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>The statistical analyses carried out in all included studies followed an intention‐to‐treat basis except <a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>. Additionally, there was imbalance of allocation in <a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>. Participants assigned to the extended‐field CRT group had a higher rate of common iliac node involvement than participants in the pelvic CRT group (36.8% with extended field RT versus 5.6% with pelvic CRT). <a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a> applied a difference technique of RT between the groups. In pelvic CRT, all participants underwent a three‐dimensional conformal radiotherapy technique (3D‐CRT). However, approximately 20% of participants allocated to extended‐field CRT underwent the intensity‐modulated radiotherapy technique (IMRT) while the remaining 80% of participants underwent 3D‐CRT. For this domain, this indicated a high risk of bias in <a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>, and low risk of bias in the other studies (<a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>). </p> </section> </section> <section id="CD012301-sec-0083"> <h3 class="title" id="CD012301-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD012301-tbl-0001"><b>Summary of findings for the main comparison</b> Extended‐field radiotherapy compared to pelvic radiotherapy for locally advanced cervical cancer</a>; <a href="./full#CD012301-tbl-0002"><b>Summary of findings 2</b> Extended‐field radiotherapy compared to pelvic chemoradiotherapy for locally advanced cervical cancer</a>; <a href="./full#CD012301-tbl-0003"><b>Summary of findings 3</b> Extended‐field chemoradiotherapy compared to pelvic chemoradiotherapy for locally advanced cervical cancer</a> </p> <p>In an attempt to cover a broad range of outcome measures, we added the rates of locoregional, distant, combined locoregional recurrences as additional secondary outcomes (see <a href="#CD012301-sec-0146">Differences between protocol and review</a>). None of the studies reported the rate of non‐para‐aortic recurrence, quality of life, and cost‐effectiveness. HRs were estimated indirectly from published data. </p> <p><a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>, <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>, and <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a> compared extended‐field RT with pelvic RT. <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a> compared extended‐field RT with pelvic CRT. <a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a> compared extended‐field CRT versus pelvic CRT. </p> <section id="CD012301-sec-0084"> <h4 class="title">Extended‐field radiotherapy versus pelvic radiotherapy alone</h4> <p>Three studies compared extended‐field radiotherapy versus pelvic radiotherapy (<a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>). </p> <section id="CD012301-sec-0085"> <h5 class="title">Primary outcomes</h5> <section id="CD012301-sec-0086"> <h6 class="title">Overall survival</h6> <p><a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a> reported OS and assessed 337 participants. We estimated HRs indirectly from published data of update report. Extended‐field RT reduced risk of death when compared to pelvic RT (HR 0.67, 95% CI 0.48 to 0.94; <a href="./references#CD012301-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012301-sec-0087"> <h6 class="title">Para‐aortic lymph node recurrence</h6> <p><a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> and <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a> reported the rate of para‐aortic lymph node recurrence. Meta‐analysis assessing 477 participants showed a lower risk of para‐aortic recurrence among participants given extended‐field RT than those given pelvic RT (RR 0.36, 95% CI 0.18 to 0.70; <a href="./references#CD012301-fig-0005" title="">Analysis 1.2</a>). The percentage of variability in effect estimates due to heterogeneity rather than to chance was not important (I² = 0%). </p> </section> </section> <section id="CD012301-sec-0088"> <h5 class="title">Secondary outcomes</h5> <section id="CD012301-sec-0089"> <h6 class="title">Progression‐free survival</h6> <p><a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a> reported four‐year PFS. Four‐year PFS of participants allocated to extended‐field RT was 53.3%, which was slightly higher than that of 49.8% in the pelvic RT group. However, we could not estimate HR and the confidence in this data due to insufficient published data. </p> <p>Updated data of <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a> reported the five‐year and 10‐year PFS (<a href="./references#CD012301-bbs2-0053" title="RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1995</a>). This study showed that there may have been little or no difference in risk of disease progression among participants given extended‐field RT compared to those given pelvic RT (HR 0.92, 95% CI 0.69 to 1.22; <a href="./references#CD012301-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD012301-sec-0090"> <h6 class="title">Locoregional recurrence</h6> <p>Meta‐analysis of three included studies, assessing 814 participants, showed no difference in risk of locoregional recurrence between participants who underwent extended‐field RT and those who underwent pelvic RT (RR 1.16, 95% CI 0.91 to 1.48; <a href="./references#CD012301-fig-0007" title="">Analysis 1.4</a>) (<a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>). The percentage of variability in effect estimates due to heterogeneity rather than to chance was not important (I² = 0%). </p> </section> <section id="CD012301-sec-0091"> <h6 class="title">Distant recurrence</h6> <p>Meta‐analysis of three studies, assessing 814 participants, showed that there may be little or no differences in risk of distant recurrence between participants who underwent extended‐field RT and those who underwent pelvic RT (RR 0.90, 95% CI 0.65 to 1.24; <a href="./references#CD012301-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>). The percentage of variability in effect estimates due to heterogeneity rather than to chance was not important (I² = 0%). </p> </section> <section id="CD012301-sec-0092"> <h6 class="title">Combined locoregional and distant recurrences</h6> <p><a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>, assessing 337 participants, found that participants given extended‐field RT had a lower risk of combined locoregional and distant metastasis than those given pelvic RT (RR 0.14, 95% CI 0.03 to 0.61; <a href="./references#CD012301-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012301-sec-0093"> <h6 class="title">Adverse events</h6> <p>Both <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a> and <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a> reported grade 3 or 4 perioperative complications but they did not specify the onset of these complications (see <a href="#CD012301-sec-0146">Differences between protocol and review</a>). Meta‐analysis, assessing 776 participants, revealed that there may have been little or no difference in risk of severe complications between participants who underwent extended‐field RT and those who underwent pelvic RT (RR 1.05, 95% CI 0.79 to 1.41; <a href="./references#CD012301-fig-0010" title="">Analysis 1.7</a>). The percentage of variability in effect estimates that was due to heterogeneity rather than to chance may have represented moderate heterogeneity (I² = 41%). </p> <p><a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> did not state the severity of complications observed in this study. We thus excluded <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> from the analysis for this outcome. </p> </section> <section id="CD012301-sec-0094"> <h6 class="title">Quality of life</h6> <p>None of the studies reported quality of life.</p> </section> <section id="CD012301-sec-0095"> <h6 class="title">Cost‐effectiveness</h6> <p>None of the studies reported cost‐effectiveness.</p> </section> </section> </section> <section id="CD012301-sec-0096"> <h4 class="title">Extended‐field radiotherapy versus pelvic chemoradiotherapy</h4> <p>One study compared extended‐field radiotherapy versus pelvic CRT (<a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>). </p> <section id="CD012301-sec-0097"> <h5 class="title">Primary outcomes</h5> <section id="CD012301-sec-0098"> <h6 class="title">Overall survival</h6> <p>Updated data of <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>, assessing 389 participants, reported a probable lower risk of death in participants undergoing pelvic CRT (HR 0.50, 95% CI 0.39 to 0.64; <a href="./references#CD012301-fig-0011" title="">Analysis 2.1</a>). </p> </section> <section id="CD012301-sec-0099"> <h6 class="title">Para‐aortic lymph node recurrence</h6> <p>Participants given extended‐field RT probably carried a lower risk of para‐aortic recurrence than those given pelvic CRT (RR 0.44, 95% CI 0.20 to 0.99; <a href="./references#CD012301-fig-0012" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD012301-sec-0100"> <h5 class="title">Secondary outcomes</h5> <section id="CD012301-sec-0101"> <h6 class="title">Progression‐free survival</h6> <p>An update data of <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a> showed that there was a probable lower risk of disease progression among participants given pelvic CRT (HR 0.52, 95% CI 0.37 to 0.72; <a href="./references#CD012301-fig-0013" title="">Analysis 2.3</a>). </p> </section> <section id="CD012301-sec-0102"> <h6 class="title">Locoregional recurrence</h6> <p>Participants undergoing extended‐field RT had higher risk of locoregional recurrence than those given pelvic CRT (RR 1.79, 95% CI 1.08 to 2.98; <a href="./references#CD012301-fig-0014" title="">Analysis 2.4</a>). </p> </section> <section id="CD012301-sec-0103"> <h6 class="title">Distant recurrence</h6> <p>There may have been little or no difference in the risk of distant recurrence between participants undergoing extended‐field RT and those who received pelvic CRT (RR 1.36, 95% CI 0.81 to 2.27; <a href="./references#CD012301-fig-0015" title="">Analysis 2.5</a>). </p> </section> <section id="CD012301-sec-0104"> <h6 class="title">Combined locoregional and distant recurrences</h6> <p>The risk of encountering combined locoregional and distant recurrences was probably higher among participants given extended‐field RT compared to those given pelvic CRT (RR 2.45, 95% CI 1.33 to 4.52; <a href="./references#CD012301-fig-0016" title="">Analysis 2.6</a>). </p> </section> <section id="CD012301-sec-0105"> <h6 class="title">Adverse events</h6> <section id="CD012301-sec-0106"> <p><b>Acute complications</b></p> <p>Participants undergoing extended‐field RT probably had a lower rate of acute grade 3 or 4 complications than those undergoing pelvic CRT (RR 0.05, 95% CI 0.02 to 0.11; <a href="./references#CD012301-fig-0017" title="">Analysis 2.7</a>). </p> </section> <section id="CD012301-sec-0107"> <p><b>Late complications</b></p> <p>There was little or no difference in the risk of late complications between participants undergoing extended‐field RT and those who received pelvic CRT (RR 1.06, 95% CI 0.69 to 1.62; <a href="./references#CD012301-fig-0018" title="">Analysis 2.8</a>). </p> </section> </section> <section id="CD012301-sec-0108"> <h6 class="title">Quality of life</h6> <p>The study did not report quality of life.</p> </section> <section id="CD012301-sec-0109"> <h6 class="title">Cost‐effectiveness</h6> <p>The study did not report cost‐effectiveness.</p> </section> </section> </section> <section id="CD012301-sec-0110"> <h4 class="title">Extended‐field chemoradiotherapy versus pelvic chemoradiotherapy</h4> <p>One small trial with relatively few events in each arm compared extended‐field CRT versus pelvic CRT (<a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>). </p> <section id="CD012301-sec-0111"> <h5 class="title">Primary outcomes</h5> <section id="CD012301-sec-0112"> <h6 class="title">Overall survival</h6> <p><a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>, assessing 74 participants, reported a probable decreased risk of death in participants receiving extended‐field CRT (HR 0.37, 95% CI 0.14 to 0.96; <a href="./references#CD012301-fig-0019" title="">Analysis 3.1</a>). </p> </section> <section id="CD012301-sec-0113"> <h6 class="title">Para‐aortic lymph node recurrence</h6> <p>There may have been little or no difference in the risk of para‐aortic recurrence between the two comparison groups (RR 0.19, 95% CI 0.02 to 1.54; <a href="./references#CD012301-fig-0020" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD012301-sec-0114"> <h5 class="title">Secondary outcomes</h5> <section id="CD012301-sec-0115"> <h6 class="title">Progression‐free survival</h6> <p>Extended‐field CRT lowered the risk of death when compared to pelvic CRT (HR 0.25, 95% CI 0.07 to 0.87; <a href="./references#CD012301-fig-0021" title="">Analysis 3.3</a>). </p> </section> <section id="CD012301-sec-0116"> <h6 class="title">Locoregional recurrence</h6> <p>There may have been little or no difference in the risk of locoregional recurrence between participants undergoing extended‐field CRT and those who received pelvic CRT (RR 0.95, 95% CI 0.20 to 4.39; <a href="./references#CD012301-fig-0022" title="">Analysis 3.4</a>). </p> </section> <section id="CD012301-sec-0117"> <h6 class="title">Distant recurrence</h6> <p>There may have been little or no difference in the risk of distant recurrence between participants undergoing extended‐field CRT and those who received pelvic CRT (RR 0.54, 95% CI 0.17 to 1.69; <a href="./references#CD012301-fig-0023" title="">Analysis 3.5</a>). </p> </section> <section id="CD012301-sec-0118"> <h6 class="title">Combined locoregional and distant recurrences</h6> <p>There may have been little or no difference in the risk of developing combined locoregional and distant recurrences between participants undergoing extended‐field CRT and those who received pelvic CRT (RR 0.24, 95% CI 0.03 to 2.02; <a href="./references#CD012301-fig-0024" title="">Analysis 3.6</a>). </p> </section> <section id="CD012301-sec-0119"> <h6 class="title">Adverse events</h6> <section id="CD012301-sec-0120"> <p><b>Acute complications</b></p> <p>There may have been little or no difference in the risk of acute complications between participants undergoing extended‐field CRT and those who underwent pelvic CRT (RR 0.95, 95% CI 0.20 to 4.39; <a href="./references#CD012301-fig-0025" title="">Analysis 3.7</a>). </p> </section> <section id="CD012301-sec-0121"> <p><b>Late complications</b></p> <p>There may have been little or no difference in the risk of late complications between participants receiving extended‐field CRT and those who received pelvic CRT (RR 0.95, 95% CI 0.06 to 14.59; <a href="./references#CD012301-fig-0026" title="">Analysis 3.8</a>). </p> </section> </section> <section id="CD012301-sec-0122"> <h6 class="title">Quality of life</h6> <p>The study did not report quality of life.</p> </section> <section id="CD012301-sec-0123"> <h6 class="title">Cost‐effectiveness</h6> <p>The study did not report cost‐effectiveness.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012301-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012301-sec-0124">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012301-sec-0185">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012301-sec-0124"></div> <section id="CD012301-sec-0125"> <h3 class="title" id="CD012301-sec-0125">Summary of main results</h3> <p>The findings of this review were based on five RCTs (seven reports). Three included studies compared extended‐field RT versus pelvic RT (<a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>). One included study compared extended‐field RT versus pelvic CRT (<a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>). One study compared extended‐field CRT to pelvic CRT (<a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>). Four included studies had participants who were only recruited after imaging or surgical lymph node excision to exclude para‐aortic lymph node disease (<a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a>; <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>; <a href="./references#CD012301-bbs2-0003" title="HaieC , PejovicMH , GerbauletA , HoriotJC , PourquierH , DeloucheJ , et al. Is prophylactic para‐aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiotherapy and Oncology1988;11(2):101‐12. ">Haie 1988</a>; <a href="./references#CD012301-bbs2-0004" title="EifelPJ , WinterK , MorrisM , LevenbackC , GrigsbyPW , CooperJ , et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para‐aortic irradiation for high‐risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90‐01. Journal of Clinical Oncology2004;22(5):872‐80. MorrisM , EifelPJ , LuJ , GrigsbyPW , LevenbackC , StevensRE , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para‐aortic radiation for high‐risk cervical cancer. New England Journal of Medicine1999;340(15):1137‐43. ">Morris 1999</a>). In <a href="./references#CD012301-bbs2-0005" title="RotmanM , ChoiK , GuseC , MarcialV , HornbackN , JohnM . Prophylactic irradiation of the para‐aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920. International Journal of Radiation Oncology, Biology, Physics1990;19(3):513‐21. RotmanM , PajakTF , ChoiK , CleryM , MarcialV , GrigsbyPW , et al. Prophylactic extended‐field irradiation of para‐aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten‐year treatment results of RTOG 79‐20. JAMA1995;274(5):387‐93. ">Rotman 1990</a>, approximately 37% of participants did not undergo any para‐aortic lymph node status evaluation. </p> <p>We observed the following main findings.</p> <p> <ul id="CD012301-list-0020"> <li> <p>Compared with pelvic RT alone, extended‐field RT probably lowered the risk of death (HR 0.67, 95% CI 0.48 to 0.94; 1 study; 337 participants; moderate‐certainty evidence; <a href="./references#CD012301-fig-0004" title="">Analysis 1.1</a>), rates of para‐aortic lymph node recurrence (RR 0.36, 95% CI 0.18 to 0.70; 2 studies; 477 participants; moderate‐certainty evidence; <a href="./references#CD012301-fig-0005" title="">Analysis 1.2</a>), with probably little or no difference in the risks of disease progression (HR 0.92, 95% CI 0.69 to 1.22; 1 study; 337 participants; moderate‐certainty evidence; <a href="./references#CD012301-fig-0006" title="">Analysis 1.3</a>) and severe adverse events (RR 1.05, 95% CI 0.79 to 1.41; 2 studies; 776 participants; moderate‐certainty evidence; <a href="./references#CD012301-fig-0010" title="">Analysis 1.7</a>). </p> </li> </ul> <ul id="CD012301-list-0021"> <li> <p>In a comparison of extended‐field RT versus pelvic CRT, participants undergoing pelvic CRT probably carried lower risks of death (HR 0.50, 95% CI 0.39 to 0.64; 1 study; 389 participants; moderate‐certainty evidence; <a href="./references#CD012301-fig-0011" title="">Analysis 2.1</a>), and disease progression (HR 0.52, 95% CI 0.37 to 0.72; 1 study; 389 participants; moderate‐certainty evidence; <a href="./references#CD012301-fig-0013" title="">Analysis 2.3</a>). Participants given extended‐field RT probably had lower risk of para‐aortic lymph node recurrence (HR 0.44, 95% CI 0.20 to 0.99; 1 study; 389 participants; low‐certainty evidence; <a href="./references#CD012301-fig-0012" title="">Analysis 2.2</a>) and severe acute adverse events (RR 0.05, 95% CI 0.02 to 0.11; 1 study; 388 participants; moderate ‐certainty evidence; <a href="./references#CD012301-fig-0017" title="">Analysis 2.7</a>). There may have been little or no difference in term of severe late adverse events among the comparison groups (RR 1.06, 95% CI 0.69 to 1.62; 1 study; 386 participants; moderate‐certainty evidence; <a href="./references#CD012301-fig-0018" title="">Analysis 2.8</a>). </p> </li> </ul> <ul id="CD012301-list-0022"> <li> <p>Compared to pelvic CRT, extended‐field CRT may have lowered the risks of death (HR 0.37, 95% CI 0.14 to 0.96; 1 study; 74 participants; very low‐certainty evidence; <a href="./references#CD012301-fig-0019" title="">Analysis 3.1</a>) and disease progression (HR 0.25, 95% CI 0.07 to 0.87; 1 study; 74 participants; very low certainty evidence; <a href="./references#CD012301-fig-0021" title="">Analysis 3.3</a>). There may have been little or no difference in the risks of para‐aortic lymph node recurrence (RR 0.19, 95% CI 0.02 to 1.54; 1 study; 74 participants; very low‐certainty evidence; <a href="./references#CD012301-fig-0020" title="">Analysis 3.2</a>) and severe adverse events (acute: RR 0.95, 95% CI 0.20 to 4.39; 1 study; 74 participants; very low‐certainty evidence; <a href="./references#CD012301-fig-0025" title="">Analysis 3.7</a>; late: RR 0.95, 95% CI 0.06 to 14.59; 1 study; 74 participants; very low‐certainty evidence; <a href="./references#CD012301-fig-0026" title="">Analysis 3.8</a>). </p> </li> </ul> </p> </section> <section id="CD012301-sec-0126"> <h3 class="title" id="CD012301-sec-0126">Overall completeness and applicability of evidence</h3> <p>We identified seven published reports from five RCTs that included comparisons of extended‐field RT/CRT with other interventions. Primary outcomes of this review included OS and para‐aortic lymph node recurrence, which three studies reported. Secondary outcomes of this review were PFS, recurrence outside of the para‐aortic area (non‐para‐aortic), acute and late severe adverse events, quality of life, and cost‐effectiveness. All included studies reported PFS, but data from one included study were insufficient for calculating an HR. </p> <p>We planned in the protocol to classify cancer recurrence into two groups including para‐aortic lymph node recurrence and non‐para‐aortic recurrence (<a href="./references#CD012301-bbs2-0067" title="ThamronganantasakulK , SupakalinN , KietpeerakoolC , PattanittumP , LumbiganonP . Extended‐field irradiation for locally advanced cervical cancer. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD012301] ">Thamronganantasakul 2016</a>). However, all included studies reported the patterns of cancer recurrences by locoregional, distant, and combined locoregional and distant recurrences. None of included studies specifically reported the rate of non‐para‐aortic recurrence. Therefore, we analysed this outcome by those that were reported in the studies. </p> <p>In addition, the review protocol stated that we intended to analyse severe adverse events by timing of onset; early and late onset (<a href="./references#CD012301-bbs2-0067" title="ThamronganantasakulK , SupakalinN , KietpeerakoolC , PattanittumP , LumbiganonP . Extended‐field irradiation for locally advanced cervical cancer. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD012301] ">Thamronganantasakul 2016</a>). Two included studies, which compared extended‐field RT versus pelvic RT alone, only reported overall severe adverse event rates. Therefore, the rate of severe adverse events in this comparison was assessed as one composite outcome. None of the studies reported data on quality of life and cost‐effectiveness. </p> <p>The following findings have to be kept in mind when considering the applicability of the evidence presented in this review. </p> <p> <ul id="CD012301-list-0023"> <li> <p>Most participants were diagnosed with squamous cell carcinoma or adenocarcinoma of the cervix, thus limiting the applicability of the existing results to women with other less common histological types. </p> </li> </ul> <ul id="CD012301-list-0024"> <li> <p>The main methods used for evaluating the status of para‐aortic lymph nodes in the included studies were older radiological imaging techniques including computed tomography (CT), magnetic resonance imaging (MRI), or lymphangiogram. Only a few participants underwent evaluation of para‐aortic lymph node by surgery. Therefore, the evidence presented may not be fully applicable to a group of women undergoing an assessment of para‐aortic lymph node status done by surgery or more advanced imaging techniques, such as a PET scan. </p> </li> </ul> <ul id="CD012301-list-0025"> <li> <p>The benefit in terms of improving OS noted among participants undergoing an extended‐field RT compared to those given pelvic RT alone was obtained from one study in which approximately 37% of participants did not undergo any para‐aortic lymph node evaluation. There were no results of subgroup analysis according to the status of para‐aortic lymph node evaluation. Extrapolation of this result in a cohort of participants given an adequate assessment of para‐aortic lymph node status would be questionable. </p> </li> </ul> <ul id="CD012301-list-0026"> <li> <p>In regard to RT technique, RT given in the comparisons of extended‐field RT versus pelvic RT alone and extended‐field RT versus pelvic CRT was accomplished through conventional techniques using megavoltage equipment. Generalisation of the findings obtained from these two comparisons to a group of participants undergoing more advanced RT techniques (i.e. 3D‐CRT or IMRT), which better focus the RT beam and cause less damage to normal tissues, should be done with great caution. </p> </li> </ul> <ul id="CD012301-list-0027"> <li> <p>In a comparison of extended‐field RT versus pelvic CRT, participants who received pelvic CRT experienced a higher rate of acute severe adverse events than would have been expected in current clinical practice. This finding should be viewed with extreme caution, especially because chemotherapy given in this study was a combination of cisplatin and fluorouracil. Therefore, the results should not be extrapolated to women receiving another chemotherapy regimen, particularly among those given single weekly cisplatin, which is the current gold‐standard concurrent chemotherapy regimen used in CRT for treating cervical cancer. </p> </li> </ul> </p> </section> <section id="CD012301-sec-0127"> <h3 class="title" id="CD012301-sec-0127">Quality of the evidence</h3> <p>It was planned in the protocol to assess the certainty of evidence by seven relevant outcomes including: OS, PFS, para‐aortic recurrence, non‐para‐aortic recurrence, severe adverse events, quality of life, and cost‐effectiveness (<a href="./references#CD012301-bbs2-0067" title="ThamronganantasakulK , SupakalinN , KietpeerakoolC , PattanittumP , LumbiganonP . Extended‐field irradiation for locally advanced cervical cancer. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD012301] ">Thamronganantasakul 2016</a>). None of the studies reported data for non‐para‐aortic recurrences, quality of life, and cost‐effectiveness. A relatively high number of participants (27.5%) in <a href="./references#CD012301-bbs2-0001" title="AsiriMA , TunioMA , MohamedR , BayoumiY , AlhadabA , SalehRM , et al. Is extended‐field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?. Cancer Management and Research2014;6:339‐48. ">Asiri 2014</a> were excluded after randomisation, thus indicating a high risk of incomplete outcome data. Other included studies had low percentages of withdrawals and dropouts, indicating a low risk of bias in this domain (see <a href="./references#CD012301-sec-0151" title="">Characteristics of included studies</a> table for proportion of participants analysed). </p> <p>As the review included only five studies, evidence was derived from relatively few studies and participants. </p> <p>Using GRADE assessments, we graded the certainty of evidence is as follows.</p> <p> <ul id="CD012301-list-0028"> <li> <p>Extended‐field RT versus pelvic RT: the evidence for all outcomes was of moderate certainty. The certainty of evidence was downgraded because of concerns regarding an imprecise estimates, as indicated by the 95% CIs. </p> </li> </ul> <ul id="CD012301-list-0029"> <li> <p>Extended‐field RT versus pelvic CRT: the evidence regarding OS, PFS, and late adverse events were of moderate certainty. The certainty of evidence for these outcomes was downgraded due to concerns regarding imprecision. The evidence for rate of para‐aortic recurrence and acute adverse events were downgraded to moderate‐certainty because of concerns regarding the serious imprecision of the pooled estimates. </p> </li> </ul> <ul id="CD012301-list-0030"> <li> <p>Extended‐field CRT versus pelvic CRT: the evidence for all outcomes was of very‐low certainty because of concerns regarding the high risk of bias and serious imprecision of the pooled results. </p> </li> </ul> </p> </section> <section id="CD012301-sec-0128"> <h3 class="title" id="CD012301-sec-0128">Potential biases in the review process</h3> <p>With assistance from the Information Specialist of the Cochrane Gynaecological, Neuro‐oncology &amp; Orphan Cancers, we were able to conduct a comprehensive literature search, including a search of the grey literature, conference proceedings and abstracts, citation lists of included studies, and registered databases of ongoing trials. In addition, bias was minimised in terms of the overall review process recommended in the <i>Cochrane Handbook for<br/> Systematic Reviews of Interventions</i> (<a href="./references#CD012301-bbs2-0029" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>As this review included only five studies, there remains the possibility of publication bias. We did not perform a funnel plot, as the analyses were limited to only one or two included studies. Because of a few included studies, we did not carry out sensitivity and subgroup analyses as previously stated in the review protocol (<a href="./references#CD012301-bbs2-0067" title="ThamronganantasakulK , SupakalinN , KietpeerakoolC , PattanittumP , LumbiganonP . Extended‐field irradiation for locally advanced cervical cancer. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD012301] ">Thamronganantasakul 2016</a>). </p> <p>There were no issues associated to bias secondary to conflicts of interests of the authors of this review. </p> </section> <section id="CD012301-sec-0129"> <h3 class="title" id="CD012301-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD012301-bbs2-0056" title="SapienzaLG , GomesMJ , CalsavaraVF , LeitaoMMJr , BaiocchiG . Does para‐aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta‐analysis of randomized clinical trials. Gynecologic Oncology2017;144(2):312‐7. ">Sapienza 2017</a> conducted a systematic review investigating the impact of extended‐field RT on the risks of distant metastasis and cancer‐related death in women with advanced‐stage cervical cancer. This review included four RCTs with several comparisons. Three included studies compared extended‐field RT versus pelvic RT alone, which were also included in the review. One RCT that <a href="./references#CD012301-bbs2-0056" title="SapienzaLG , GomesMJ , CalsavaraVF , LeitaoMMJr , BaiocchiG . Does para‐aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta‐analysis of randomized clinical trials. Gynecologic Oncology2017;144(2):312‐7. ">Sapienza 2017</a> included compared preoperative <sup>18</sup>F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) with those not given the tomography (<a href="./references#CD012301-bbs2-0011" title="TsaiCS , LaiCH , ChangTC , YenTC , NgKK , HsuehS , et al. A prospective randomized trial to study the impact of pretreatment FDG‐PET for cervical cancer patients with MRI‐detected positive pelvic but negative para‐aortic lymphadenopathy. International Journal of Radiation Oncology, Biology, Physics2010;76(2):477‐84. ">Tsai 2010</a>). Participants with extrapelvic metastasis on FDG‐PET received pelvic RT alone and the remainder of participants received extended‐field RT. <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a>, which was also included in <a href="./references#CD012301-bbs2-0056" title="SapienzaLG , GomesMJ , CalsavaraVF , LeitaoMMJr , BaiocchiG . Does para‐aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta‐analysis of randomized clinical trials. Gynecologic Oncology2017;144(2):312‐7. ">Sapienza 2017</a>, compared extended‐field RT and pelvic RT in 36 women who underwent RT as a primary treatment and 57 women who received RT following radical hysterectomy. <a href="./references#CD012301-bbs2-0056" title="SapienzaLG , GomesMJ , CalsavaraVF , LeitaoMMJr , BaiocchiG . Does para‐aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta‐analysis of randomized clinical trials. Gynecologic Oncology2017;144(2):312‐7. ">Sapienza 2017</a> pooled the results of four RCTs for para‐aortic lymph node recurrence and distant recurrence and two RCTs for cancer‐related death. They noted that extended‐field RT reduced the rate of para‐aortic recurrence (HR 0.53, 95% CI 0.19 to 0.64) and other distant metastases (HR 0.69, 95% CI 0.50 to 0.96), but conferred no clear difference in the risk of cancer‐related death between the comparison groups (HR 0.68, 95% CI 0.45 to 1.01). </p> <p>There are important differences between the review by <a href="./references#CD012301-bbs2-0056" title="SapienzaLG , GomesMJ , CalsavaraVF , LeitaoMMJr , BaiocchiG . Does para‐aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta‐analysis of randomized clinical trials. Gynecologic Oncology2017;144(2):312‐7. ">Sapienza 2017</a> and the present review. Firstly, the outcomes to each comparison type were examined and the effects of extended‐field RT more thoroughly separately analysed and we assessed the impact on OS, PFS, locoregional recurrence, and severe adverse events. Secondly, the present review question was more specific. The review was only interested in assesing if there was any clinical benefit and the possible harm of extended‐field RT given as a primary treatment for locally cervical cancer. Therefore, data for only 36 participants who were assigned to receive RT as a primary treatment in <a href="./references#CD012301-bbs2-0002" title="ChataniM , MatayoshiY , MasakiN , NarumiY , TeshimaT , InoueT . Prophylactic irradiation of para‐aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Strahlentherapie Und Onkologie1995;171(11):655‐60. ">Chatani 1995</a> were extracted. Thirdly, we excluded <a href="./references#CD012301-bbs2-0011" title="TsaiCS , LaiCH , ChangTC , YenTC , NgKK , HsuehS , et al. A prospective randomized trial to study the impact of pretreatment FDG‐PET for cervical cancer patients with MRI‐detected positive pelvic but negative para‐aortic lymphadenopathy. International Journal of Radiation Oncology, Biology, Physics2010;76(2):477‐84. ">Tsai 2010</a> as the participants were not randomly assigned to the types of RT given. </p> <p>However, we do agree with <a href="./references#CD012301-bbs2-0056" title="SapienzaLG , GomesMJ , CalsavaraVF , LeitaoMMJr , BaiocchiG . Does para‐aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta‐analysis of randomized clinical trials. Gynecologic Oncology2017;144(2):312‐7. ">Sapienza 2017</a> that applicability of the current evidence to the modern day practice may be limited. The RT techniques and chemotherapy regimens used in the previous studies are now outmoded for many clinical settings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012301-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. RCT: randomised controlled trial; RT: radiotherapy." data-id="CD012301-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. RCT: randomised controlled trial; RT: radiotherapy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012301-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012301-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 1 Overall survival." data-id="CD012301-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 2 Para‐aortic lymph node recurrence." data-id="CD012301-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 2 Para‐aortic lymph node recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 3 Progression‐free survival." data-id="CD012301-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 3 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 4 Locoregional recurrence." data-id="CD012301-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 4 Locoregional recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 5 Distant recurrence." data-id="CD012301-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 5 Distant recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 6 Combined locoregional/distant recurrence." data-id="CD012301-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 6 Combined locoregional/distant recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 7 Adverse events (onset not specified)." data-id="CD012301-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Extended‐field radiotherapy (RT) versus pelvic RT, Outcome 7 Adverse events (onset not specified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 1 Overall survival." data-id="CD012301-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 2 Para‐aortic lymph node recurrence." data-id="CD012301-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 2 Para‐aortic lymph node recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 3 Progression‐free survival." data-id="CD012301-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 3 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 4 Locoregional recurrence." data-id="CD012301-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 4 Locoregional recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 5 Distant recurrence." data-id="CD012301-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 5 Distant recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 6 Combined locoregional/distant recurrence." data-id="CD012301-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 6 Combined locoregional/distant recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 7 Acute adverse events." data-id="CD012301-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 7 Acute adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 8 Late adverse events." data-id="CD012301-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT), Outcome 8 Late adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 1 Overall survival." data-id="CD012301-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 2 Para‐aortic lymph node recurrence." data-id="CD012301-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 2 Para‐aortic lymph node recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 3 Progression‐free survival." data-id="CD012301-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 3 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 4 Locoregional recurrence." data-id="CD012301-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 4 Locoregional recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 5 Distant recurrence." data-id="CD012301-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 5 Distant recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 6 Combined locoregional/distant recurrence." data-id="CD012301-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 6 Combined locoregional/distant recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 7 Acute adverse events." data-id="CD012301-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 7 Acute adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012301-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/urn:x-wiley:14651858:media:CD012301:CD012301-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_t/tCD012301-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 8 Late adverse events." data-id="CD012301-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Extended‐field chemoradiotherapy (CRT) versus pelvic CRT, Outcome 8 Late adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/media/CDSR/CD012301/image_n/nCD012301-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012301-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Extended‐field radiotherapy compared to pelvic radiotherapy for locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Extended‐field radiotherapy versus pelvic radiotherapy for locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant:</b> women with locally advanced cervical cancer undergoing radiotherapy as a primary treatment<br/> <b>Setting:</b> specialised hospital<br/> <b>Intervention:</b> extended‐field radiotherapy<br/> <b>Comparison:</b> pelvic radiotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pelvic radiotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with extended‐field radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.67</b><br/> (0.48 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HR was calculated, assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Para‐aortic lymph node recurrence</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> <p>(23 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b> </p> <p>(0.18 to 0.70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.92</b><br/> (0.69 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way, HR was calculated, assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>357 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000<br/> (282 to 503) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/> (0.79 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>776<br/> (2 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="#CD012301-sec-0146">Differences between protocol and review</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to a wide 95% confidence interval.<br/> <sup>b</sup>Downgraded one level due to wide confidence intervals crossing the line of no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Extended‐field radiotherapy compared to pelvic radiotherapy for locally advanced cervical cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012301-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Extended‐field radiotherapy compared to pelvic chemoradiotherapy for locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Extended‐field radiotherapy versus pelvic CRT for locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant:</b> women with locally advanced cervical cancer undergoing radiotherapy as a primary treatment<br/> <b>Setting:</b> specialised hospital<br/> <b>Intervention:</b> extended‐field radiotherapy<br/> <b>Comparison:</b> pelvic CRT </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pelvic chemoradiotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with extended‐field radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall surviva</b>l </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.50</b><br/> (0.39 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HRs are calculated, assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Para‐aortic lymph node recurrence</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (19 to 92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b><br/> (0.20 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.52</b><br/> (0.37 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HRs are calculated, assumed and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>646 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (13 to 71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.05</b><br/> (0.02 to 0.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>388<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Late adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000<br/> (122 to 285) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/> (0.69 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision, as indicated by a 95% CI.<br/> <sup>b</sup>Downgraded two levels level due to serious imprecision: wide 95% CI with few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Extended‐field radiotherapy compared to pelvic chemoradiotherapy for locally advanced cervical cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012301-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Extended‐field chemoradiotherapy compared to pelvic chemoradiotherapy for locally advanced cervical cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Extended‐field CRT versus pelvic CRT for locally advanced cervical cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant:</b> women with locally advanced cervical cancer undergoing CRT as a primary treatment<br/> <b>Setting:</b> specialised hospital<br/> <b>Intervention:</b> extended‐field CRT<br/> <b>Comparison:</b> pelvic CRT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pelvic CRT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with extended‐field CRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.37</b><br/> (0.14 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HRs are calculated, assumed, and corresponding risks were not estimated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Para‐aortic lymph node recurrence</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (3 to 214) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.19</b><br/> (0.02 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.25</b><br/> (0.07 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a result of the way HRs are calculated, assumed and corresponding risks were not estimated </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/> (17 to 366) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/> (0.20 to 4.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Late adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (2 to 405) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/> (0.06 to 14.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CRT:</b> chemoradiotherapy; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias: the included study had a high risk of bias in three key domains assessed.<br/> <sup>b</sup>Downgraded two levels due to serious imprecision: small sample size and few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Extended‐field chemoradiotherapy compared to pelvic chemoradiotherapy for locally advanced cervical cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/full#CD012301-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012301-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Extended‐field radiotherapy (RT) versus pelvic RT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Para‐aortic lymph node recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.18, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Locoregional recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.91, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Distant recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.65, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Combined locoregional/distant recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events (onset not specified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.79, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Extended‐field radiotherapy (RT) versus pelvic RT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012301-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Para‐aortic lymph node recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Locoregional recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Distant recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Combined locoregional/distant recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Acute adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Late adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Extended‐field radiotherapy (RT) versus pelvic chemoradiotherapy (CRT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012301-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Extended‐field chemoradiotherapy (CRT) versus pelvic CRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Para‐aortic lymph node recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Locoregional recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Distant recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Combined locoregional/distant recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Acute adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Late adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Extended‐field chemoradiotherapy (CRT) versus pelvic CRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012301.pub2/references#CD012301-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012301.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012301-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012301-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012301-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012301-note-0002">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012301-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012301-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012301-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012301\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012301\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012301\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012301\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012301\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012301.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012301.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012301.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012301.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012301.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717885857"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012301.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717885861"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012301.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc2d7f9cb9377',t:'MTc0MDcxNzg4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 